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Chemistry

Mass spectrometric characterization and fluorophore-assisted light inactivation of human
excitatory amino acid transporter 2.
Chairperson: Richard J. Bridges
Glia-expressing excitatory amino acid transporter 2 (EAAT2) mediates the bulk of
glutamate re-uptake in the human central nervous system (CNS) and is associated with a
variety of neurological disorders. Our understanding of the structure and mechanism of
this integral membrane protein is limited. The goal of this study was to use
pharmacological, mass spectrometric (MS) and photochemical approaches to probe
EAAT2. For MS characterization, a hexahis epitope was incorporated into the Nterminus of human EAAT2. The recombinant protein was functionally expressed in
HEK 293T cells and purified through a single-step nickel column. In-gel and in-solution
trypsin digestions were conducted on the isolated protein. Overall, eighty-nine percent
sequence coverage of the protein was achieved. An 88-amino acid tryptic peptide
covering the proposed substrate binding site was revealed after N-deglycosylation. This
study provided an efficient and simple method to purify, digest and characterize integral
membrane proteins by MS. In addition, the EAAT2 peptide fingerprint obtained by
digestion offered a template for later protein modification studies. In an effort to design
photoaffinity labels for hEAAT2, a series of aryl diaminopropionic acids and aryl
aspartylamide compounds were synthesized and characterized as potent EAAT inhibitors.
Compounds containing 9-fluorenone groups were found to be able to irreversibly
inactivate EAATs under UV-A illumination. The mechanism underlying the photoinactivation was shown to be singlet oxygen mediated protein oxidation. The specificity
of the photo-inactivation was illustrated by the protection effects of inhibitors, as well as
the proximity between the transporter and ligands. Trypsin digestion and MS analyses
revealed a mass change of a peptide from hEAAT2 binding pocket in the photoinactivated protein. Molecular docking results supported our speculation that a
tryptophan residue was oxidized during the photo-inactivation. The identification of
possible EAAT2 photo-inactivation site provided additional information for the location
of the EAAT2 lipophilic interaction domain.
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CHAPTER 1

STRUCTURE, FUNCTION AND PHARMACOLOGY OF
EXCITATORY AMINO ACID TRANSPORTERS (EAATS)

1.1 L-Glutamate as a Neurotransmitter

In addition to its role in protein synthesis, L-glutamate is an essential amino acid
in mammalian cellular metabolism. The deamination of L-glutamate yields αketoglutarate, an important intermediate in the TCA cycle. In amino acid metabolism,
the degradation of L-glutamate represents an amino group source for transamination
reactions. Glutamate dehydrogenase catalyses the glutamate deamination reaction that is
also involved in nitrogen metabolism. In addition, L-glutamate also serves as a precursor
for other small molecules, including glutathione.
It has been known for a long time that glutamate exists in high levels in the brain.
The average concentration of glutamate in the human brain is estimated to be around 10
mM. The first series of observations on the excitatory action of L-glutamate on neurons
were made by Curtis and colleagues (Curtis et al., 1960; Curtis et al., 1961). However,
the role of L-glutamate as an excitatory amino acid (EAA) in the neurotransmission was
not fully established until the 1980s, when NMDA and non-NMDA receptors were
identified as the synaptic receptors that are responsible for glutamate-mediated excitation
in cat spinal Renshaw cells (reviewed in Watkins and Jane, 2006). With a better

1

understanding of the components, function and distribution of the EAA system, Lglutamate is now clearly recognized as the major excitatory neurotransmitter in the
mammalian central nervous system (CNS). Current estimates suggest that about 30-40%
of the synapses in the mammalian CNS are glutamatergic (Nieoullon et al., 2006).
Glumatergic neurons are localized in nearly all regions of the brain, with particularly high
densities in the areas involved in learning and memory, such as cerebral cortex and
hippocampus.

1.2 Glutamate Neurotransmission (Figure 1.1)
In the brain, glutamate is synthesized via two routes: the transamination of αoxoglutarate and the metabolism of glutamine. Glutamine is synthesized in glial cells,
transported into presynaptic neurons, and convered to glutamate by the neuro-specific
enzyme glutaminase. In presynaptic glutamatergic neurons, L-glutamate is packaged into
synaptic vesicles by the vesicular glutamate transporter (VGLUT1, 2 and 3). The uptake
of L-glutamate into the vesicles is driven by a proton electrochemical gradient generated
by the vacuolar type ATPase. It was estimated that each synaptic vesicle contains
anywhere from 400 - 5,000 glutamate molecules (Clements et al., 1992; Barbour and
Hausser, 1997). Glutamate is released from synaptic vesicles via exocytosis in response
to the action potential-induced presynaptic membrane depolarization and increased Ca2+
concentrations in active zones. During release, the glutamate concentration in the
synaptic cleft quickly rises to the millimolar range (Diamond and Jahr, 1997). The
released glutamate
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Figure 1.1. L-Glutamate-mediated neurotransmission in a typical glutamatergic
synapse (adapted from Sheldon and Robinson, 2007). Glutamate receptors shown in
the figure: NMDA receptor, AMPA receptor, mGluRs. Glutamate transporters shown
in the figure: EAAT1, EAAT2, EAAT3, VGLUT1. Other proteins participating in
glutamate neurotransmisson: glutamate/cystine exchanger system Xc-, glial glutamine
transporter system N, neuronal glutamine transporter system A. Glutamate is
converted into glutamine by glutamine synthase in astrocytes; glutamine is converted
back to glutamate by glutaminase in neurons to complete the glutamine-glutamate
cycle.
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in the synaptic acts on postsynaptic neurons through the activation of a wide variety of
postsynaptic excitatory amino acid (EAA) receptors.

1.2.1 Glutamate Receptors
Based on pharmacology, structures, and functional properties, EAA receptors can
be categorized into two major classes: ionotropic glutamate receptors (iGluRs) and
metabotropic glutamate receptors (mGluRs). The classification of postsynaptic glutamate
receptors has been based primarily on the agonist sensitivity. Ionotropic glutamate
receptors are ligand-gated ion channels that are responsible for the depolarizing actions of
L-glutamate action. Three main subtypes of iGluRs are NMDA (NR1, NR2A-D, NR3),
AMPA (GluR1-4) and kainate receptors (GluR5-7, KA1-2). Functionally, AMPA and
kainate receptors (or non-NMDA receptors) are voltage-independent ion channels that
mediate fast excitatory synaptic transmission. Activation of these receptors induces
postsynapse depolarization, primarily through the gating of Na+ currents. NMDA
receptors, on the other hand, are ligand-gated and voltage-dependent ion channels that
mediate slower synaptic signaling. Membrane depolarization and glutamate binding
induce the release of Mg2+ from the NMDA receptor channel that then allows the influx
of Ca2+ and activation of a variety of cellular pathways. In addition to the glutamate site,
there are multiple sites through which the activity of the NMDA receptor can be
regulated, including a co-agonist glycine site, a polyamine site, and a phencyclidine (PCP)
site where noncompetitive inhibitors such as MK-801 bind. The combination of its
voltage dependency and Ca2+ permeation provide a mechanism through which NMDA
receptors contribute to higher order processes such as long-term potentiation (LTP), long-
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term depression (LTD) and synaptic plasticity (Bliss and Collingridge, 1993). Not
surprisingly, the NMDA receptor has also become a potentially important therapeutic
target.
The other major family of glutamate receptors are mGluRs, which are linked to
G-proteins and second-messenger systems. Structurally they exhibit many of the features
common to all G-protein coupled receptors (GPCRs). Functionally, mGluRs exert their
actions through the regulation of protein phosphorylation and second-messenger cascades.
The mGluRs are subdivided into 3 groups based upon pharmacological differences and
downstream effectors: group I (mGluR1, mGluR5) and II (mGluR2, mGluR3) are
activated by trans-ACPD, while group III receptors (mGluR4, mGluR6, mGluR7,
mGluR8) are activated by L-AP4. Group I metabotropic glutamate receptors are coupled
to phospholipase C while groups II and III receptors are coupled to adenylate cyclase
(Schoepp et al., 1999).

1.2.2 Excitotoxicity
In addition to its role in excitatory signaling, the activation of iGluRs can also
induce neuronal pathology. This process is referred to as excitotoxicity and involves
several pathological pathways. Most importantly, rapid increases in intracellular Ca2+
that follow the excessive activation of NMDA receptors, can trigger both necrotic and
apoptotic pathways and ultimately result in cell death. Energy consumption and
increased rates of reactive oxygen species (ROS) generation are also associated with the
over activation of glutamate receptors and mitochondria damage. Excitotoxicity is now
well-recognized as a primary or secondary mechanism underlying the pathology observed
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in growing number of acute insults to the CNS (e.g., ischemia, hypoglycemia, spinal cord
injury, traumatic brain injury), as well as chronic neurological and neuropsychological
disorders (e.g., amyotrophic lateral sclerosis, epilepsy, schizophrenia, Huntington's
disease, Alzheimer’s disease) (Natale et al., 2006; Foster and Kemp, 2006; Waxman and
Dijb-Hajj, 2005; Hynd et al., 2004; Olney, 2003; Rao and Bredesen, 2004; Coyle, 2004).

1.2.3 Glutamate Transporters
The rapid and efficient clearance of extracellular L-glutamate into neurons and
glia by the EAATs is believed to contribute to the termination of its excitatory signal, the
recycling of the neurotransmitter, and the prevention of excitotoxicity. The role of
EAATs in controlling excitatory neurotransmission is achieved by the high expression
level of the transporters near the synapse, as well as the high binding affinities for Lglutamate. The combination of both factors allows the transporters to overcome their
slow operation time (10-75 ms) and efficiently clear the extracellular L-glutamate
(Wadiche et al., 1995; Bergles and Jahr, 1997). Another aspect of the EAATs’ function
in terminating excitatory signal lies in the regulation of glutamate spillover. Controlled
extrasynaptic signaling may have significant roles in processes associated with learning
and memory, such as LTP (Vizi and Mike, 2006). Transporter expression patterns and
functional studies using inhibitors suggested that the majority of released L-glutamate is
recycled into glial cells via EAAT1 and EAAT2-mediated mechanism. These
neurotransmitters are subsequently converted into glutamine which serves as the
precursor to glutamate in the glutamate-glutamine cycle. The transport of L-glutamate
into neurons by EAAT3, although only accounts for a small percentage of the total
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glutamate uptake, has functional importance in supplying a precursor for GABA
synthesis (Mathews and Diamond, 2003) and glutathione synthesis (Aoyama et al., 2006).
The role of EAATs in preventing excitotoxicity was first demonstrated by the high
neuronal death observed in isolated neuronal culture but not in neuronal-glial co-culture
when high concentrations of L-glutamate were included in the buffers (Rosenberg et al.,
1992). Several in vitro studies also showed blocking EAATs with inhibitors potentiated
excitotoxicity (Robinson et al., 1993; Dugan et al., 1995) and induced necrotic
neurodegeneration (Guiramand et al., 2005; Bonde et al., 2005). In addition, GLT-1
(EAAT2) knockout mice display lethal spontaneous seizures and exacerbation of cortical
injury that can be attributed to elevated L-glutamate levels (Tanaka et al., 1997).
Alterations in glutamate transporter activities and expressions have been found in
a variety of neurological disorders. Amyotrophic lateral sclerosis (ALS) is probably the
most extensively studied disease that has the connection with EAATs. It was observed
that expression levels of EAAT2 were significantly reduced in ALS patients (Rothstein et
al., 1995). Recent evidence suggested that the loss of EAAT2 is due to the selective
cleavage of the EAAT2 via activation of caspase 3 by superoxide dismutase 1 (SOD1)
mutants in ALS patients (Boston-Howes et al., 2006). Instead of having a primary link
between transporters’ pathology, as in ALS, excitotoxicity plays a role in many other
neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease
(PD), Huntington’s disease (HD) and stroke. In both AD and HD, reduced surface
expression of EAAT2 was observed (Masliah et al., 2000; Brustovetsky et al., 2004).
The associations between PD and glutamate toxicity were based on the neuroprotective
effects offered by NMDA receptor antagonists (Klockgether and Turski, 1990) but the
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direct connection with EAATs is still unknown. During a cerebral stroke, the glutamate
concentration in the cebrebrospinal fluid (CSF) is significantly elevated. An EAAT2
promoter polymorphism was recently found to downregulate the EAAT2 expression after
stroke, which may have increased the likelihood of excitotoxic damage (Mallolas et al.,
2006).

1.3 EAAT Subtypes

Molecular cloning studies in the 1990s successfully identified five membrane
protein subypes, termed EAAT1-5 (in humans) that are responsible for glutamate
reuptake (Storck et al., 1992; Tanaka, 1993; Pines et al., 1992; Kanai and Hediger, 1992;
Fairman et al., 1995; Arriza et al., 1997). The five subtypes share 50%-60% sequence
homology and they belong to solute carrier 1 (SLC1) family, along with neutral amino
acid transporters ASCT1 and ASCT2. The localization of EAATs differs among
subtypes; with EAAT1 and EAAT2 are primarily localized in glia cells, EAAT3 and
EAAT4 are generally considered to be neuronal, and EAAT5 is highly restricted to the
retina. In most brain areas, EAAT2 is responsible for the majority of glutamate uptake
(Haugeto et al., 1996).
1.4 Regulation of EAATs

When compared to the monoamine family of neurotransmitter transporters, the
regulation of glutamate transporters is just beginning to be understood. There is evidence
showing that the EAATs are associated with cholesterol-rich lipid raft microdomains
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(Butchbach et al., 2004; Raunser et al., 2006). The targeting of transporters into such
domains requires interacting scaffolding proteins. Rothstein and colleagues have
identified a few interacting scaffolding proteins of EAAT3 and EAAT4 such as GTRAPs
(Jackson et al., 2001; Lin et al., 2001) and RTN2B (Liu et al., 2008). While the GTRAPs
all interact with the C-termini of the transporters, a LIM protein Ajuba, was found to
interact with N-terminus of EAAT2 and suggested to be part of a protein complex that
stabilizes the transporter at the plasma membrane (Marie et al., 2002). Protein kinases
and phosphatases such as PKC and PP2A have been shown to regulate the activities of
glutamate transporters (Gonzalez and Robinson, 2004). Protein phosphorylation and
dephosphorylation seem to have different effects on different EAAT subtypes (Gonzalez
et al., 2002, 2003) and the exact mechanisms are still unclear. The interacting proteins
involved in regulating EAAT trafficking and internalization have yet to be identified.

1.5 EAAT Mechanism

The process of transporting glutamate into the cell against its concentration
gradient by EAATs is driven by the coupled-influx of Na+ and efflux of K+ down their
respective concentrations gradients. The current kinetic model suggests that the
translocation of one glutamate molecule into the cell is coupled with the inward cotransport of three Na+ and one H+. After the release of glutamate, one K+ binds to the
empty carrier before being exported to the extracellular space (Zerangue and Kavanaugh,
1996). The electrogenic nature of glutamate transporters has also allowed their actions to
be studied electrophysiologically. Substrates induce currents, while non-substrate
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inhibitors themselves do not, but can block substrate-induced currents. This transport
cycle has to be completed before glutamate can be concentrated in the cells. A rat GLT-1
mutant E404D that lacks K+-binding ability has been shown to only operate in the
exchange mode, i.e. glutamate re-binds empty carrier intracellularly and is exported.
This “alternate access model” would require the transporter protein to have an external
gate and an internal gate. The exact location of both gates and the conformational
changes associated with the translocation process has yet to be elucidated, although
recent crystallographic data (see below) have begun to provide some insight.

1.6 EAAT Pharmacology

The cloning of each subtypes of glutamate transporters allowed researchers to
develop heterogeneous expression models, such as Xenopus oocytes, C17.2 and HEK 293
cell lines, to study the subtype-selectivity of the drugs. These systems provide an
advantage over native brain preparations, such as synaptosomes where cross-reactivity
among subtypes and with various receptors can not be easily separated. The endogenous
substrates of EAATs, L-glutamate and L-aspartate, are efficiently transported into cells
by all five subtype, along with several closely related analogues including D-aspartate
(Figure 1.2). Many of the inhibitors identified do not possess the ability to be
translocated into the cells and are thus referred to as non-substrate inhibitors.
Recognizing the structural differences between substrates and non-substrate inhibitors
will greatly advance our understanding of the protein binding domain structure, transport
mechanism and the development of therapeutic drugs targeting these transporters.
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The search for potent, subtype-selective glutamate transporter inhibitors in the
past 20 years has yielded a large collection of compounds that differ greatly in structure,
potency and subtype-specificity. The developments in EAAT pharmacology have been
covered in several excellent reviews (Bridges et al., 1999; Shigeri et al., 2004; Bridges
and Esslinger, 2005; Dunlop and Butera, 2006). Rather than revisiting the history of
EAAT pharmacology, the major classes of EAAT inhibitors and their representative
compounds are described.
Early attempts in designing EAAT inhibitors took the approach of simple
substitutions on the glutamate or aspartate backbones (Figure 1.3). Methylation on C3
and C4 positions of L-glutamate produced two inhibitors with different EAAT inhibitory
profiles. Threo-3-methylglutamate (T3MG) preferentially inhibits EAAT2 over EAAT1
and EAAT3, while being a substrate of EAAT4 (Vandenberg et al., 1997; Eliasof et al.,
2001). The 4-methylated glutamate, (2S,4R)-4-methylglutamate, is a non-substrate
inhibitor of EAAT2 and a less potent, but transportable substrate of EAAT1 (Aprico et al.,
2001, 2004). Isosteric replacements of the γ-carboxyl group into sulphonic acid and
hydroxamic acid groups generated a substrate of EAAT1, L-serine-O-sulfate (L-SOS),
and a nonspecific inhibitor in L-aspartate-β-hydroxamic acid.
The free rotation of the sigma bonds in linear glutamate analogues made it
difficult to probe the ligand-protein interaction sites. Bridges and colleagues developed a
series of conformationally constrained glutamate/aspartate analogues (Figure 1.4) and
were able to generate EAAT pharmacophores based on these compounds (Esslinger et al.,
2005). One of the first of this group is dihydrokainate (DHK) (Sonnenberg et al., 1996),
and still remains one of the best EAAT2-selective inhibitors. The selectivity of DHK
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displayed on EAAT2 is more than 100 fold over EAAT1 and EAAT3 in various
expression systems (Arriza et al., 1994). Other categories of conformationally
constrained analogues include 2-(carboxycyclopropyl)glycines (CCGs),
aminocyclobutane cicarboxylates (ACBDs) and pyrrolidine dicarboxylates (PDCs). Most
of these compounds showed comparable inhibition potencies across the EAAT subtypes.
Hydroxyl- substitution on the C3 of L-aspartate affords L-threo-β-hydroxyaspartate (L-β-THA), a substrate inhibitor of EAAT1-3 (Arriza et al., 1994). While L-βTHA did not receive a lot of attention, further substitutions on the β- hydroxyl group
yielded a series of breakthrough inhibitors that were a major advance in EAAT
pharmacology (Figure 1.5). The pharmacological characterization of DL-threo-βbenzyloxyasparate (DL-TBOA) (Shimamoto et al., 1998) and its derivatives (Shimamoto
et al., 2000) demonstrated that compounds bearing large lipophilic groups have the
potential to be very potent EAAT inhibitors. Both TBOAs and threo-βnapththyloxyaspartates (TNOAs) have IC50 values in low micromolar range on all
subtypes. One of the most potent EAAT inhibitors reported to date is (2S,3S)-3-{3-[4(trifluoromethyl)benzoylamino]benzyloxy}aspartate (TFB-TBOA), with IC50 values of
22 nM, 17 nM and 300 nM on EAAT1-3, respectively (Shimamoto et
al., 2004). Removal of the ether linkage in TBOA resulted in a subtype specific inhibitor,
L−β-threo-benzylaspartate (TBA), which showed a 10-fold preference for the EAAT3
(Esslinger et al., 2005). Additional TBA derivatives have also been recently
characterized (Mavencamp et al., 2008).
The reports of a new family of very potent EAAT inhibitors bearing
diaminopropionic acids or aspartylamide scaffolds and large lipophilic groups seemed to
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validate the conclusions that the lipophilic interactions between the transporters and the
ligands are key contributors to the pharmacological activity (Greenfield et al., 2005;
Dunlop et al., 2005) (Figure 1.6). Compounds such as (S)-2-amino-4-(4-(2-bromo-4,5difluorophenoxy)phenylamino)-4-oxobutanoic acid (WAY-213613) and (S)-4-(9Hfluoren-2-ylamino)-2-amino-4-oxobutanoic acid (NBI-59159) have shown low
nanomolar range IC50s on EAATs. It is also worth mentioning that this family of nonsubstrate inhibitors displayed very unusual binding kinetics to the EAATs, with
association and dissociation times in the 10-20 minute range. This kinetic feature may
also contribute to the high potency by elevating the local concentration in the aqueous
bowl of the transporter trimer.

1.7 EAAT Structures

Early predictions of EAAT structures have generally agreed on the first 6
transmembrane domains on the N-termini of the proteins. Extensive site-directed
mutagenesis work was performed in the late 1990s and early 2000s to probe the
seemingly unstructured C-termini of the EAAT family proteins (Slotboom et al., 2001;
Seal et al., 1998; Grunewald et al., 1998). Despite controversies over a few residues, it is
now accepted that there are two additional transmembrane regions and two loops, one
from the cytoplasmic side and the other from the extracellular side, traverse halfway
through the plasma membrane before coming back to the same side of the membrane
(Seal et al., 2000; Grunewald et al., 2002). Mutations in these regions often times
resulted in the partial or total loss of

17

Br
O
F
F

O
N
H

O

NH2
COOH

N
H

NH2
COOH

NBI-59159

WAY-213613

Figure 1.6. Aryl aspartylamides are the most potent group of EAAT inhibitors
identified to date with low nanomolar IC50 values.
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activity of the transporters. These data suggested that C-terminal side of the protein is
associated with the binding and translocation of glutamate.
Our understanding of glutamate transporter structures was greatly advanced after
the successful crystallization of a bacteria glutamate/aspartate transporter GltPh (Yernool
et al., 2004, PDB accession code: 1XFH). The glutamate transporter homolog from
Pyrococcus horikoshii, shares about 30-40% primary sequence identity with the human
EAATs and preferentially transports aspartate. The solved crystal structure in many
aspects agreed well with the predictions made based on biochemical observations. In
addition, it also offered a much clearer picture of the structural features of glutamate
transporters. The transporters form a trimeric structure with an aqueous bowl in the
center. The secondary structure features eight transmembrane domains and two hairpin
loops, HP1 and HP2. The authors proposed a model in which HP2 serves as the
extracelluar gate and HP1, part of TM7 and TM8 form the intracellular gate (Figure 1.7).
However, the modest resolution of the structure (3.5 Å) limited the dynamic
conformational change information that could be provided by this structure. To follow
up this study, high-resolution, inhibitor- and ion-bound glutamate transporters were
crystallized and solved by X-ray diffraction (Boudker et al., 2007). In a series of
structures (PDB accession codes: 2NWW, 2NWX, 2NWL), the authors were able to
demonstrate the transporter conformations in different binding modes. One particularly
interesting finding was the non-transportable inhibitor, D,L- threo-β-benzyloxyaspartate
(TBOA), kept the transporter in an open conformation by placing the bulky benzyl group
against the tip of the HP2, therefore prevented the extracellular gate from closing and
completing the pocess of intracellular release. Because of the high sequence homology in
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Figure 1.7. Secondary structure illustration of GltPh (adapted from Torres and Amara,
2007). Model was created based on the crystal structures of GltPh from Pyrococcus
horikoshii (Yernool et al., 2004; Boudker et al., 2007).
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Figure 1.8. Tertiary structure of human EAATs based on the sequence alignment
against GltPh. Image was rendered using MacPymol (DeLano Scientific,
http://www.delanoscientific.com/).

21

the regions of functional significance between GltPh and human EAATs, it is quite
possible the human glutamate transporters operate by similar mechanisms (Figure 1.8).

1.8 Conclusions

Given their wide distribution in the CNS and important functions in excitatory
signaling and excitotoxicity, glutamate transporters represent an interesting target for
ligand and drug development. Any subtle change of EAAT activity will likely induce a
dramatic alteration to local synaptic environment. The development of subtype-specific
inhibitors is a key step towards drug discovery targeting different populations of EAATs.
However, such study has been hindered by the incomplete understanding of the
transporter structures and the protein-inhibitor interactions.
Although the GltPh structures shed light on the structures and mechanisms of
human EAATs, several key questions still remain to be answered. Protein conformation
changes are associated with the movement of the substrate from the external binding site
to the internal releasing site. The dynamic nature of this movement is still lacking from
the image of TBOA-bound GltPh. Furthermore, the high potency exhibited by aryl
aspartylamides and aryl diaminopropionic acidss can not be easily explained by the
binding site and orientation of TBOA in GltPh. Additional efforts need to be focused on
delineating the lipophilic pocket of EAATs in general and more importantly, subtype
differences.
With an increasing amount of structural, functional and pharmacological data
available for the EAATs, the stage is now set for the development and use of
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pharmacological probes to investigate structural features of the EAATs that will
ultimately provide a better understanding of their structure and function.
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CHAPTER 2

EXPRESSION, PURIFICATION, DIGESTION AND MASS
SPECTROMETRIC ANALYSIS OF HUMAN EXCITATORY AMINO
ACID TRANSPORTER 2 (EAAT2)

2.1 Introduction

Integral membrane proteins (IMPs) are a set of proteins that accounts for about
one third of all predicted proteomes (Wallin and von Heijne, 1998; Stevens and Arkin,
2000). IMPs play key roles in essential cell functions, such as receptors signaling,
transport and trafficking. Structure-function relationship studies have always been a
preferred path to understand the functions and dysfunctions of proteins and their roles in
human disease. While X-ray crystallographic and NMR-based approaches represent
some of the best methods to reveal protein structural information, solving structures
specifically for membrane proteins remains a challenge due to the difficulties in handling
such proteins. Indeed, among over 53,000 known protein crystal structures solved
(http://www.rcsb.org) at atomic resolution, only about 170 of them are for membrane
proteins.
The size and complexity of a full proteome easily exceed the dynamic range of
any single analytical method (Domon and Aebersold, 2006). Over the last 15 years, mass
spectroscopy (MS) techniques have emerged as a powerful tool in analyzing structures
and functions of biological macromolecules (Tanaka et al., 2003; Karas and Hillenkamp,
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1988; Fenn et al., 1989). The availability of using different instruments and techniques
provides a wide range of structural and functional analyses. However, the problems in
characterizing integral membrane proteins also poses a challenge to MS techniques
(Whitelegge et al., 2003; Wu and Yates III, 2003) because membrane proteins: 1) have
poor solubility in aqueous buffers; 2) are typically lower in abundance; 3) are usually
unstable and easily form aggregates; 4) often undergo conformational and folding
changes; 5) exhibit various forms of post-translational modifications (PTMs). To address
the above limitations, modern proteomics studies on membrane proteins employ a
number of strategies related to membrane solubilization, including the use of organic
solvents (Blonder et al., 2002; Goshe et al., 2003), detergents (Han et al., 2004) and
organic acids (Washburn et al., 2001). Protein purification methods such as Immobilized
Metal Affinity Chromatography (IMAC) have also been used to enrich and separate
membrane proteins (Porath, 1992). The establishments of proteomics data standards,
such as the human protein reference database (Peri et al., 2003; http://www.hprd.org) and
SwissProt (Bairoch et al., 2005; http://www.pir.uniprot.org), provide platforms to share
PTM information in public databases. Along with the rapid progresses in MS
instrumentation and techniques, a large number of integral membrane proteins have been
characterized by MS methods, inicluding human tetraspain membrane protein CD81
(Takayama et al., 2008), human cannabinoid CB2 receptor (Zvonok et al., 2007) and a
yeast G-protein coupled receptor Ste2p (Lee et al., 2007).
The selection of detergents in the extraction and purification of membrane
proteins is especially important. This choice can greatly effect the purification efficiency
and also the downstream MS analysis. Typically, however, the identification of
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appropriate detergents in membrane protein purification is determined on a protein-byprotein basis. For example: 3-[(3-cholamidopropyl) dimethylammonio]propanesulfonate (CHAPS) and n-dodecyl-β-D-maltoside (DDM) were used to solubilize
the κ opioid receptor (Wannemacher et al., 2008), 1% SDS was chosen in a study of
vesicular glutamate transporter 1 (Cox et al., 2008), and DDM was successfully used in
the mass spectrometric characterization of human cannabinoid CB2 receptor (Filppula et
al., 2004). Generally, in proteomic studies, proteins are resolved on one-dimensional or
two-dimensional gels and visualized using various stains. Two-dimensional SDS-PAGE
has an exceptionally high separation capacity, e. g. up to 10,000 proteins on one gel.
However, in the instance of membrane proteins, solubilized proteins are prone to
precipitation during isoelectric focusing in 2D-gel (Santoni et al., 2000). For this reason,
many researchers preferred 1D-gel in studying membrane proteins (Ferro et al., 2002;
Galeva and Altermann, 2002; Simpson, 2000). The increased protein complexity
problem in 1D gel can be overcome by the use of IMAC prior to the gel electrophoresis.
Once the proteins are resolved on gels and protein bands of interest are selected,
they are digested into peptides that are then extracted from the gel for the subsequent
identification by MS. Tryptic digestion is one of the most widely used methods to cleave
proteins. Trypsin specifically hydrolyzes peptide bonds at the carboxyl side of lysine and
arginine residues (Keil-Dlouha et al., 1971).
In this study, human excitatory amino acid transporter 2 (EAAT2) was expressed
in mammalian cells, extracted, purified and characterized by MS. The MS
characterization of this transporter protein provided us a structural template for further
protein-ligand interaction studies.
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2.2 Materials and Methods

2.2.1 Materials
Laboratory chemical and buffers were from Sigma Chemical Co. (St. Louis, MO)
and Fisher Chemical (Pittsburgh, PA). Protease inhibitor cocktail was from Roche
Applied Science (Indianapolis, IN). HisTrap chelating columns were from GE Healthcare
(Piscataway, NJ). Sequencing-grade modified trypsin was from Promega (Madison, WI).
Peptide calibration standards were from Bruker Instruments (Billerica, MA) and
Invitrogen (Carlsbad, CA).

2.2.2 Construction of Hexahistidine-tagged hEAAT2
hEAAT2 cDNA was PCR amplified from pBlueScripthEAAT2 (provided by Dr
M. Kavanaugh) using primer pairs (forward; 5’ATTAGGATCCATGGCATCTACGGAAGGTG-3’ and reverse 5’TATTGATATCTTATTTCTCACGTTTCCA-3’). The primer pair introduced BamHI
sites at the 5’end and EcoRV sites at the 3’ end of the amplified fragment. The PCR
fragment was then subcloned into the BamHI and EcoRV sites within the polylinker of
the AAV vector pAM-CAG-WPRE (kindly provided by Dr Mathew During, University
of Auckland, NZ) to create pAM-CAG-EAAT2-WPRE. Final clones were confirmed by
double stranded sequencing. A 96 b.p. HIS-Xpress insert was PCR amplified from
pBAD/HIS B (Invitrogen) using primer pairs 5’-TTT GGA TCC ACC ATG GGG GGT
TCT CAT-3’ and 5’-ATT GGA TCC CTT ATC GTC ATC GTC GTA-3’ introducing
BAMHI sites to the 5’ and 3’ ends of the fragment. The PCR fragment was subcloned
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into pCR-BLUNT-TOPO (Invitrogen) according to the manufacture's protocol. Positive
clones were mini-prepped and the reading frame and sequence were confirmed by double
strand sequencing analysis at the Murdock Lab sequencing facility at the University of
Montana. The fragment was isolated by BAMHI digestion, purified and subcloned into
pAM/CAG-EAAT2 plasmid at the 5’-end of the gene, generating an N-terminal fusion
protein. The correct orientation was confirmed by restriction analysis and PCR
amplification.

2.2.3 Cell Culture and Transfection
HEK 293T cells (ATCC, Manassas, VA) between passages 10 and 20 were
cultured at 37 °C in a humidified atmosphere containing 5% CO2 in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 1 mM sodium
pyruvate, 0.1 mM nonessential amino acids solution, and 0.05% penicillin–streptomycin
(5000 units/ml) and gentamicin sulfate (0.05 mg/ml). Cells were seeded at 1 x 105
cells/well in 12-well plates for transporter activity experiments and 1.5 x 106 cells/dish in
100 mm2 dishes for membrane preparations. At 48 h after plating, cells were transfected
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) or FuGENE Transfection Reagent
(Roche, Indianapolis, IN) in a ratio of 2 ml of Lipofectamine to 2 mg of purified plasmid
DNA in accordance with the manufacturer's instructions.

2.2.4 Transporter Activity
Approximately 24 hours after transfection, near-confluent HEK 293T cells were
rinsed with a physiological buffer (138 mM NaCl, 11 mM d-glucose, 5.3 mM KCl, 0.4
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mM KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES, pH
7.4) and allowed to preincubate at 37 °C for 5 min. Uptake was initiated by replacing the
pre-incubation buffer with buffer containing 25 mM D-[3H]-aspartate. Following a 5 min
incubation, the media was removed by rapid suction and the cells rinsed three times with
ice-cold buffer. The cells were dissolved in 0.4 N NaOH for 24 h and analyzed for
radioactivity by liquid scintillation counting and protein by the BCA (Pierce) method.
Transport rates were corrected for background, i.e., radiolabel accumulation at 4 °C.
Initial studies confirmed that uptake quantified in this manner was linear with time and
protein levels and that uptake in untransfected HEK 293T cells was indistinguishable
from background.

2.2.5 Membrane Preparation and Immobilized Metal Affinity Chromatography (IMAC)
Approximately 24 hours after transfection, near-confluent HEK 293T cells were
rinsed with DPBS (MediaTech, Manassas, VA) after the culture medium was aspirated.
Cells were harvested in DPBS with 5mM dithiothreitol (DTT) and EDTA-free cmplete
protease inhibitor (Roche, Indianapolis, IN). The cell suspension was homogenized in
0.2 M sucrose with 5 mM DTT, then centrifuged at 500 g for 5 min. The pellet was
discarded and the membrane fraction was centrifuged at 13,000g for 30 min. The
membrane pellet was resuspended in 1 ml IMAC suspension buffer containing 0.5 M
NaCl, 0.02 M sodium phosphate, 1% n-dodecyl-β-D-maltoside (DDM), 30% glycerol, 5
mM DTT and 2 mg/ml asolectin. The membrane suspension was incubated in 4 °C for 8
h, then centrifuged at 14,000 g for 3 min and supernatant was applied to the 1 ml HisTrap
High Performance nickel-sepharose column (GE Healthcare, Piscataway, NJ), the flow
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through fraction was collected, and the column was washed with 15 ml of buffer
containing 0.5 M NaCl, 0.02 M sodium phosphate, 20 mM imidazole, 0.1% DDM, 30%
glycerol and 2 mg/ml asolectin. The 6xHIS hEAAT2 was eluted with buffer containing a
gradient concentration of imidazole ranging from 50 mM to 300 mM, or a single-step
elution of 300 mM imidazole.

2.2.6 Western Blotting
For detection of the hEAAT2 by western immunoblotting, samples were mixed
with 2x Laemmli buffer and resolved by SDS-PAGE using 4-15% gradient gels, then
transferred to PVDF membranes (Bio-Rad, Hercules, CA). Membranes were blocked for
1 h in 0.1% dried milk, 20 mM Tris base, 130 mM NaCl, 0.1% Tween 20, pH 7.6,
followed by overnight incubation at 4 °C with rabbit anti-GLT-1 polyclonal antibody
(Affinity Bioreagents, Golden, CO). Membranes were then washed and incubated with
anti-rabbit IgG Horseradish Peroxidase (HRP)-linked antibody (Cell Signaling, Danvers,
MA) for 1 h at room temperature and developed using ECL western blot
chemiluminescence reagent (Cell Signaling, Danvers, MA). Fujifilm LAS 3000 iamging
system (Bio-Rad, Hercules, CA) was used to capture chemiluminescence.

2.2.7 SDS-PAGE for In-gel Digestion
Fractions containing the purified hEAAT2 from the HisTrap column were
concentrated from 500 ml to 20 ml using Microcon YM50 filters (Millipore, Billerica,
MA). The concentrated sample was mixed with 2x Laemmli buffer and loaded onto a 4-

30

15% SDS-PAGE gel, then stained with Biosafe Coomassie (Bio-Rad). Gel image was
taken by a Biorad Molecular Imager ChemiDoc XRS system.

2.2.8 Intact Protein MALDI-TOF Analysis
Intact purified hEAAT2 protein was not reduced or alkylated before being
precipitated in 10% trichloroacetic acid (TCA) at 4 °C for 30 min. The protein pellet was
collected by centrifugation at 15,000g for 5 min. The protein pellet was then washed with
1 ml of cold 1:1 ethanol:ether (v:v) solution 3 times. The washed pellet was briefly airdried and resuspended in 50% acetonitrile and 0.1% TFA. An aliquot of the solution was
mixed with equal volume of sinapic acid matrix solution in 50% acetonitrile and 0.3%
TFA before being spotted onto a MALDI plate. A Bovine Serum Albumin mass spec
standard (Sigma-Aldrich, St. Louis, MO) was used for calibration.

2.2.9 Protein Deglycosylation
Purified hEAAT2 protein from HisTrap column was concentrated by Millipore
Microcon YM-50 filter to a concentration of 1.1 mg/ml. A denaturant solution containing
2% octyl-b-D-glucopyranoside and 100 mM 2-mercaptoethanol was added followed by
the addition of 500 units/ml PNGase F (from Elizabethkingia meningoseptica, SigmaAldrich, St. Louis, MO) at the ratio of 50 units per mg of protein. The solution was mixed
and incubated at 37 °C for 1 h. This enzyme recognizes the N-glycosylation sites of
glycoproteins and cleaves the linkage between Asn and carbohydrate chain (Tarentino
and Plummer, 1994). The reaction was stopped by adding appropriate volume of 2x
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Laemmli sample buffer and reaction products were analyzed on SDS/PAGE or Western
immunoblotting.

2.2.10 In-Solution Digestion
Aliquot of purified hEAAT2 from HisTrap column was precipitated in 10% TCA
at 4 °C for 30 min. The protein pellet was collected by centrifugation at 15,000g for 5
min. The protein pellet was then washed with 1 ml of cold 1:1 ethanol:ether (v:v) solution
3 times. The washed pellet was briefly air-dried and resuspended in 50 mM ammonium
bicarbonate buffer, pH 8.0 (AMBIC). Sequence grade trypsin (Promega, Madison, WI)
was added at a 1:20 ratio, and digestion was allowed to proceed at 37 °C for 20 h. Tryptic
peptides were analyzed from the digest solution.

2.2.11 In-Gel Digestion
The SDS-PAGE gel fragment was diced into 1 mm3 pieces and destained twice
with 200 ml 50% acetonitrile/25 mM AMBIC, for 1 h to remove the Coomassie blue dye.
Gel pieces were then dried in a SpeedVac (Savant) at room temperature. Prior to
digestion, gel pieces were reduced with 10 mM DTT in 100 mM ammonium bicarbonate
at 56 °C for 1 h, then alkylated with 55 mM iodoacetamide in ammonium bicarbonate for
1 h at room temperature in the dark. Gel pieces were washed with 50% acetonitrile/25
mM ammonium bicarbonate and dehydrated in SpeedVac. Tryptic digestion was started
with the addition of 50 mg reconstituted trypsin per mg of EAAT2 protein in 25 mM
NH4HCO3 at pH 8.0. The concentration of the trypsin solution was 12.5 ng/ml. After
reswelling, excess trypsin solutions were removed and the gel pieces were covered with
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an overlay of ~20 ml of 25 mM ammonium bicarbonate. The protein was digested for 20
h at 37 °C.

2.2.12 MALDI-TOF MS Analysis
MALDI-TOF analysis was performed on a Voyager DE PRO (Applied
Biosystems, Foster City, CA). For whole protein analysis, 0.5 ml of sample was spotted
onto the target plate followed by spotting an equal volume of sinapic acid matrix solution
in 50% acetonitrile and 0.3% TFA. A bovine serum albumin mass spec standard (SigmaAldrich, St. Louis, MO) was used for calibration. For peptide analysis, an aliquot of
sample was mixed with an equal volume of CHCA matrix solution in 50% acetonitrile
and 0.1% TFA, and 1 ml was spotte onto the target plate. A Bruker peptide standard was
used for calibration. For average masses obtained in linear mode, mass accuracy was set
at 200 ppm; for monoisotopic masses obtained in reflectron mode, mass accuracy was set
at 50 ppm. Masses were searched against the NCBI protein database or a hEAAT
database using Mascot (www.matrixscience.com). Modifications for
carbamidomethylated cysteines and partial methionine oxidation were included.
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2.3 Results and Discussion

2.3.1 Expression and Transporter Activity
Our intent was to carry out structural studies on human EAAT2 (hEAAT2) that
would provide greater mechanistic insight into the how substrates and inhibitors interact
with this transporter during the process binding and translocation. hEAAT2 belongs to
the solute carrier family 1 (SLC1) proteins that also includes EAATs 1, 3-5, ASCT1 and
ASCT2 (Hediger et al., 2004). Owing to the inherent problems associated with the
isolation and structural characterization of integral membrane proteins, it is not surprising
that few, if any, MS studies have been carried out on members of this family. The
challenges readily exemplified by reports that hEAAT2 is a protein without a defined
molecular weight (Lehre et al., 1995), is extremely unstable in solution and easy forms
SDS-resistant oligomers (Trotti et al., 1998). Previously, efforts have been made to
purify the rat homologue of hEAAT2, GLT-1. Danbolt et al. fractionated solubilized
brain membranes with lectin affinity chromatography, followed by chromatography on
hydroxyapatite and DEAE-cellulose (Danbolt et al., 1990). More recently, Semliki Forest
virus particles carrying a HIS-tagged GLT-1 gene were used to infect BHK-21 cells from
which the transporter protein was subsequently purified through IMAC (Raunser et al.,
2005). In the present work, we chose to employ a routinely-used mammalian cell line
(HEK 293T) to express the recombinant protein, as it allowed for more direct
comparisons of SAR data, as well as simplified the purification to an one-step process for
fast MS characterization.
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Based upon numerous biochemical characterizations, and ultimately confirmed in
the GltPh crystal structures, both termini of the hEAAT2 are localized to the cytoplasmic
side of the plasma membrane. These, as well as site-directed mutagenesis studies, also
led to the conclusion that that the substrate and ion binding domains are located near the
C-terminus of hEAAT2. To minimize any potential effect on ligand binding, a 6XHIS
hEAAT2 vector was constructed with the epitiope located on the N-terminus of hEAAT2.
HEK 293T cells transiently transfected with 6XHIS hEAAT2 cDNA were assayed for
transporter activity by quantifying the uptake of D-[3H]-aspartate 24 h after transfection.
D-Aspartate is commonly used as a substrate in these assays as it reduces the
complications associated with radiolabel metabolism. We found that 6XHIS hEAAT2
expressed in HEK 293T cells is fully functional and closely mimics the activity native
hEAAT2 (Figure 2.1). The Vmax and Km for D-aspartate uptake were calculated to be 4,318
± 734 pmol/min per mg protein and 140 ± 49 µM, respectively, for the 6XHIS hEAAT2
and 3,594 ± 267 pmol/min per mg protein, and 106 ± 18 µM, respectively, for the native
transporter. It is also worth noting that expression of hEAAT2 in HEK 293T cells yield
much higher levels of activity and protein than other established mammalian cell
expression systems. For example, hEAAT2 expressed in neural progenitor cell line C17.2
exhibited a Vmax of 501 ± 72 pmol/min per mg protein under the same assay conditions
(Esslinger et al., 2005). The pharmacological specificity of the HIS-tagged transporter
was also confirmed by characterizing its sensitivity to the well known blockers.
Dihydrokainate (DHK) and L-glutamate reduced the levels of hEAAT2-mediated uptake
of D-[3H]-aspartate (25 µM) to 55% and 45% of control, respectively, when included in
the assays at 100 µM.
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Figure 2.1. Transport activities of 6XHIS hEAAT2 and non-tagged hEAAT2
expressed in HEK 293T cells. The transport rates were measured by including D-[3H]aspartate in the substrate solution and counting the total radioactivity uptaken by
transporter-expressing cells. Conditions for radiolabeled kinetic assay are described in
Experimental Section.
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2.3.2 Membrane Solubilization and Protein Purification
Solubilization of membrane protein pellets often requires high salt concentrations,
strong detergents, organic solvents (Blonder et al., 2004) and/or organic acids (Washburn
et al., 2001). However, these methods are often not compatible with downstream IMAC
purification and MS analysis. In light of this, we developed a membrane isolation method
that effectively separated and enriched the 6XHIS hEAAT2 proteins as indicated by
hEAAT2 immunoreactivity (Figure 2.2, lanes 2-5). To obtain sufficient amounts of
membrane protein for the purification of 6xHIS hEAAT2, transfected HEK 293T cells
were plated in 100 mm2 dishes at a density of 2 x 106 cells/dish. Two dishes were used for
each membrane preparation. Dithiothreitol (DTT) was included in the lysis buffer and the
suspension buffer at a concentration of 5 mM to prevent cysteine cross-linking. We
attempted to solubilize the membrane pellets with several solvent systems and detergents.
It was found that at least 0.5 M NaCl was required to effectively solubilize the protein.
Among the detergent solutions tested (1% SDS, 2% CHAPS, 2% octyl-β-D-glucoside
and 1% DDM), only 1% DDM effectively solubilized the 6XHIS hEAAT2 membrane
pellet and was able to prevent the nonspecific binding of other cellular proteins to the
IMAC column. DDM is a gentle nonionic detergent that has been shown to enhance
protein delipidation and protein mobility in the solubilization and purification of several
membrane proteins including glycerol-3-phosphate transporter GlpT (Auer et al., 2001)
and the human glucose transporter, Glut1 (Boulter et al., 2001). The improved mobility
of the transporter was readily observed in our column purification experiments, as the
membrane pellets solubilized with the other detergents had trouble eluting from the
columns. Consistent with previous observations of the instability of hEAAT2 in solution
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Figure 2.2. Western blot analysis of hEAAT2 immunoreactivity in HEK 293T cell
membrane preparation. Cells were homogenized in 0.2 M sucrose with 5 mM DTT
and then centrifuged at 500g for 5 min. The pellet was solubilized in 1x Laemmli
buffer (lane 5) and the supernatant (lane 2) was centrifuged at 13,000g for 30 min.
The resulting pellet was solubilized in column buffer (lane 3) and fraction of
supernatant (lane 4) was loaded onto the SDS-PAGE. The addition of asolectin in the
suspension buffer (lane 6) significantly improved monomer/oligomer ratio under the
same conditions.
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and its tendency to form aggregates (Trotti et al., 1998), a significant amount of
oligomeric proteins was observed in our initial membrane preparations (see Western blot
in Figure 2.2, lanes 2, 3). The addition of asolectin (2 mg/ml, Raunser et al., 2005) to the
suspension buffer greatly increased the monomer/oligomer ratio as illustrated by Western
blot analysis (Figure 2.2, lane 6).
The solubilized membrane fraction containing the 6XHIS hEAAT2 was applied to
a HisTrap Ni2+ column. Following a 15 ml wash, the column was eluted with sequential
applications of 4 ml volumes of elution buffer containing increasing concentrations
imidazole (50-300 mM). The 6XHIS hEAAT2 eluted in the fractions containing 150 mM
and 200 mM imidazole (Figure 2.3A, lanes 5, 6). Isolated protein was quantified by
Bradford Assay and BCA assay (Pierce). Using this protocol, the average yield of a
single preparation from 2 confluent 100mm2 dishes of transfect cells was about 300 µg of
protein. As has been previously reported for native glutamate transporters21, Western blot
analysis of the 6XHIS hEAAT2 yielded a wide, fuzzy band that lacked defined edges and
had an apparent mass of 70-80 kDa. Given that the calculated molecular weight of
6XHIS hEAAT2 is 66 kD and that hEAAT2 is known to be a glycoprotein with two Nglycosylation sites (Danbolt et al., 1992), we treated an aliquot of the suspended protein
with peptide-N-glycosidase (PNGase) F. This enzyme cleaves the linkages between Asn
and carbohydrate chain at N-glycosylation sites. PNGase F treatment resulted in a shift
of the monomer 6XHIS hEAAT2 band to around 65 kDa (Figure 2.3B). The observed
~10 kDa change in size is in agreement with the mass of the N-linked glycans on GLT-1
(Danbolt et al., 1992) and suggested that the 6XHIS hEAAT2 expressed in HEK 293T
cells is fully glycosylated at both sites. In contrast, only partial glycosylation of the
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Figure 2.3. IMAC purification of 6XHIS hEAAT2. (A) Western blot probed with
anti-GLT-1 antibody to detect recombinant 6XHIS hEAAT2. Lane 1: crude
membrane precolumn contain 6XHIS hEAAT2. Lane 2: 1:200 dilution of 50 mM
imidazole fraction eluted from the Ni2+-chelating column. Lane 3: 1:200 dilution of
100 mM imidazole fraction eluted from the Ni2+-chelating column. Lane 4: Biotin
ladder standard. Lane 5: 1:200 dilution of 150 mM imidazole fraction eluted from the
Ni2+-chelating column. Lane 6: 1:200 dilution of 200 mM imidazole fraction eluted
from the Ni2+-chelating column. (B) Western blot probed with anti-GLT-1 antibody to
show the glycosylation of 6XHIS hEAAT2. Lane 1: 1:200 dilution of 200 mM
imidazole fraction eluted from the Ni2+-chelating column. Lane 2: deglycosylated
6XHIS hEAAT2 treated by PNGase F. (C) Coomassie blue stained SDS-PAGE gel
(20 µl of the following samples). Lane 1: 200 µl of 150 mM imidazole fraction eluted
from the Ni2+-chelating column concentrated by Microcon filter. Lane 2: same amount
of sample deglycosylated by PNGase F treatment.
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transporter was observed when GLT-1 was expressed in BHK-21 cells (Raunser et al.,
2005). Isolated fractions containing 6XHIS hEAAT2 were concentrated by Microcon
filters and resolved on SDS-PAGE gels. When gels were stained with Coomassie, a
predominant band around 75 kDa was also observed (Figure 2.3C, lane 1), consistent
with Western blot analysis, deglycosylation with PNGase F produced a band around 65
kDa (Figure 2.3C, lane 2). Despite the inclusion of DTT and asolectin in the buffer, the
isolated 6XHIS hEAAT2 remained relatively unstable in solution as evidenced by either
precipitation or aggregate formation on gels. We also observed that freezing precipitated
the protein out of solution such that it could not be re-dissolved. Similarly, storage of the
protein solution for more than a week at 4 °C resulted in the extensive SDS-resistant
aggregation of 6XHIS hEAAT2.

2.3.3 Intact 6XHIS hEAAT2 Protein Analysis by MALDI-TOF
In order to determine an accurate mass for the isolated protein, MALDI-TOF
analysis was performed on the intact protein following its elution from IMAC. Protein
was precipitated with 10% TCA (final concentration) to desalt and remove detergents and
washed with ethanol:ether 1:1 before being dissolved into 50% acetonitrile and 0.1%
TFA. Aliquot of the solution was then mixed with equal volume of sinapinic acid matrix
and spotted on the target plate. Sonication was used when proteins could not be
completely dissolved. The MALDI spectrum of the intact protein displayed a singly
charged monomer peak with a molecular mass of 76,451 ± 20 Da (Figure 2.4A). No
dimer or multimer peaks were observed. The experimental mass determined by MALDI-
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Figure 2.4. MALDI-TOF mass analysis of native (A) and in-gel trypsin-digested (B,
C, D), purified 6XHIS hEAAT2. Panel B: Mass spectrum obtained in reflectron
mode. The monoisotopic masses are shown. Panel C: Mass spectrum obtained in
linear mode. The average masses are shown.
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TOF matched the apparent mass observed on the Western blot and Coomassie-stained
SDS-PAGE.

2.3.4 In-gel Trypsin Digestion and MALDI-MS
An in-gel approach was first used to characterize 6XHIS hEAAT2 protein
isolated from IMAC. Briefly, gel pieces were destained in 25 ammonium bicarbonate
(AMBIC) solution in 50% acetonitrile, reduced in 10 mM DTT in 100 mM AMBIC and
alkylated in 55 mM iodoacetamide in 100 mM AMBIC. Trypsin solution in 25 mM
AMBIC (final concentration 12.5 ng/µl) was added to speedvac-dried dried pieces and
the reaction was allowed to proceed for 20 h in 37 °C. Tryptic peptides were extracted by
100 µl of 0.1% TFA in 60% acetonitrile. Peptide solutions were vacuum-dried in
speedvac and resuspended in 0.1% TFA in 50% acetonitrile solution for MALDI-TOF.
Both linear mode and reflectron mode of the MALDI-TOF produced similar spectra, with
more peptides > 2,000 Da observed in linear mode (Figure 2.4B). Experimental masses
were searched against the human database of the protein sequences in NCBInr using
MASCOT. Peptides containing cysteines were identified as the carbamidomethylated
species, consistent with a complete reduction and alkylation. A few methionine
oxidations were also observed, together with a proline to pyro-glutamate modification in
the peptide SADCSVEEEPWKR (1592.70 Da, 1606.70 Da modified peptide). The
source of the identified peptides from the in-gel digestions were evenly distributed
between transmembrane domains and intracellular/extracellular regions. Tryptic
fragments NDEVSSLDAFLDLIR (1706.9 Da, GRAVY = 0.073) and
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TSVNVVGDSFGAGIVYHLSK (2050.1 Da, GRAVY = 0.500) generated the strongest
ion signals.
As previously mentioned, there are two predicted N-glycosylation sites on
hEAAT2, both of which were found on the same tryptic peptide:
VLVAPPPDEEANATSAVVSLLNETVTEVPEETK (3448.8 Da; GRAVY = -0.073).
This peptide was not observed following the in-gel digestion of the glycosylated protein,
but was readily observed in the spectra of deglycosylated 6XHIS hEAAT2. This
suggested that N-glycosylation did occur at the predicted sites and likely prevented the
peptide from being identified. Overall, the in-gel trypsin digestion of 6XHIS hEAAT
yielded about 40% sequence coverage of the 66 kDa protein (Table 2.1). Considering the
hydrophobic nature of this integral membrane protein (GRAVY = 0.332), the resulting
sequence coverage is much higher than that of most in-gel digestions reported. For
example, a18% sequence coverage was achieved following the in-gel digestion of
VGLUT1 (Cox et al., 2008).
While the extent of overall sequence coverage was higher than expected, this
protocol fell somewhat short with respect to our goal of visualizing the peptides from the
proposed drug binding regions. An alignment of the hEAAT2 sequence with the crystal
structure of the homologous bacterial glutamate/aspartate transporter GltPh suggests that
substrates and inhibitors bind to the region traversing HP1, TMD7, HP2 and TMD8 of
hEAAT2 (Figure 2.5). However, our in-gel trypsin digestion protocol yielded only 20%
coverage of this 153 amino acid sequence (Figure 2.7). A computationally-based mock
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Figure 2.5. Amino acid sequence of the N-terminal 6XHIS-tagged human EAAT2.
The transmembrane domains are marked in bold and the hairpin loops are marked in
italic. Secondary structure predictions are based on the sequence alignment of
hEAAT2 against crystal structure of GltPh (PDB entry: 2NWW).

45

digestion (ProteinProspector, UCSF) of hEAAT2 predicted an 88 amino acid fragment
covering TMD7, HP2 and part of TMD8. The length and hydrophobic nature (GRAVY
= 1.147) of this peptide may have precluded its extraction from the gel matrix, even if it
had been liberated during the digestion.

2.3.5 In-solution Trypsin Digestion and MALDI-MS
As suggested above, peptide recovery from in-gel digestions can be low because
of the difficulties in extracting large, hydrophobic peptides from gel matrices. For this
reason, in-solution methods have become a preferred option for membrane protein MS
characterizations as exemplified by studies on the human cannabinoid CB2 receptor
(Zvonok et al., 2007), bacteriorhodopsin (Blonder et al., 2002), and vesicular glutamate
transporter VGLUT1 (Cox et al., 2008). Further, the in-solution digestion performed on
lens aquaporin 0 AQP0 suggested that the addition of organic solvents, such as
acetonitrile, could improve the digestion efficiency for integral membrane proteins (Han
and Schey, 2004). The in-solution trypsin digestion of 6XHIS hEAAT2 was carried out
following direct precipitation with 10% TCA. The resulting pellet was washed with
ethanol:ether to remove detergents and residual TCA. The protein pellet was collected by
centrifugation before being dissolved into one of the three digestion buffers: 50 mM
AMBIC, 50 mM AMBIC with 10% acetonitrile or 50 mM AMBIC in 60% methanol.
Trypsin was added at an enzyme to protein ratio of 1:20. The reaction was allowed to
proceed at 37 °C for 20 h, after which the digestion solution was vacuum-dried in a
speedvac. The peptides were resuspended in 0.1 TFA, 50% acetonitrile. Trypsin
digestion in 50 mM AMBIC with 10% acetonitrile yielded a spectrum with slightly more
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peptides than 50 mM AMBIC alone. In contrast, digestion in 60% MeOH produced very
few identifiable peptides. This may be attributable to the differential solubility of TCAprecipitated protein pellets in each of the solvent systems. Alternatively, purified proteins
were reduced in 5 mM TCEP and alkylated in 100 mM iodoacetamide prior to TCA
precipitation. The resulting peptides did not differ in sequence from the peptides
identified from native conditions. This suggested reduction and alkylation didn't improve
the sequence coverage of in-solution digestion method in our study.
In contrast to peptides identified from in-gel digestion which are mainly short and
hydrophilic, the in-solution digestion produced generated many longer, hydrophobic
peptides. Searching the human database of the protein sequences in NCBInr using
MASCOT, we were able to identify multiple 6XHIS hEAAT2 tryptic fragments from
MALDI-TOF m/z scans ranging from 500 – 3,000 Da, 2,000 – 6,000 Da and 4,000 –
10,000 Da (Figure 2.6). The identified peptides covered 7 out of 8 transmembrane
domains with the exception of TMD4. In the region of the presumed binding pocket, we
were able to identify HP1 as a single peptide
KNPFSFFAGIFQAWITALGTASSAGTLPVTFR (3,405.9 Da, GRAVY = 0.559).
Moreover, the 88 amino acid fragment predicted from the in silico tryptic digestion was
identifiable only following in-solution digestion of the 6XHIS hEAAT2. The possible
origin of this peptide was examined in greater detail using PNGase F. Comparisons
between digestions in the presence and absence of PNGase F confirmed with high
confidence that the 9,013 Da peptide was indeed this tryptic fragment in 6XHIS
hEAAT2. These finding indicate that glycans are linked to two Asn residues (Asn241
and Asn251 in 6XHIS hEAAT2) in the extracellular space between TMD3 and TMD4
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blocked and are consistent with the idea that the entry of trypsin to this specific region of
the protein was likely limited. Crystallography studies on GltPh revealed that monomers
form a trimeric structure surrounding a ~65 Å aqueous bowl. The function of this bowl
is unclear, as evidence from kinetic studies suggest each monomer works independently
(Yernool et al., 2004; Boudker et al., 2007). More recently, it has been hypothesized that
this structural arrangement of trimers may serve to increase the local concentration of
substrates and inhibitors and influence their kinetics, as exemplified in studies with the
potent hEAAT3 inhibitor, NBI-59159 (Bridges et al., 2008). It was also reported that
deglycosylation of GLT-1 does not affect its activity, but could possibly stabilized
transporters in solution and membrane (Raunser et al., 2005). The spatial proximity of
these glycans to the binding pocket raise interesting questions as to the possible
functional influences that glycosylation may have on glutamate transport.
In-solution digestion solutions were vacuum-dried in speedvac and resuspended
in several other solvents including: 5% formic acid in 50% acetonitrile, 50% formic acid
and FAPH (50% formic acid, 25% acetonitrile, 15% isopropanol, and 10% water) buffer
followed by MALDI-MS. No additional peptides were identified using these solutions.
Indeed, none of the tested solution produced more peptides than 0.1% TFA in 50%
acetonitrile. The sequence coverage of the 6XHIS hEAAT2 by in-solution digestion after
deglycosylation was 77% (Table 2.1). It is noteworthy that the coverage of the
hypothesized hEAAT2 substrate binding domain markedly increased from 20% via in-gel
digestion to 91% via in-solution method. Overall, combing in-gel and in-solution
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Figure 2.6. MALDI-TOF mass analysis of in-solution trypsin digestion of purified
6XHIS hEAAT2. Panel A: Mass spectrum of small, hydrophilic peptides in 50%
acetonitrile, 0.1% TFA. Panel B: Mass spectrum of large, hydrophobic peptides
identified after N-deglycosylation by PNGase F. All m/z values shown are average
masses.
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Figure 2.7. Trypsin 6XHIS hEAAT2 coverage map of MALDI-TOF analysis. Amino
acids are color coded to represent the digestion method used in their identification.
Blue = in-gel only. Green = in-solution only. Red = both in-gel and in-solution.
Approximately 89% (544/609) sequence coverage of the protein was obtained.
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Table 2.1a. MALDI-TOF Identification of Peptides from 6XHIS hEAAT2 Digested
with Trypsin.
peptide position

m/z observed (Da)

in-gel

001-025
001-052
026-047
053-064
053-071
076-122
101-122
101-125
101-150
123-146
155-183
184-192
194-208
209-228
230-262
263-272
315-334

2610.48 mi
5562.39 avg
2405.68 mi
1366.42 mi
2238.16 avg
4931.46 avg
2438.49 avg
2811.03 avg
5317.59 avg
2558.32 avg
3056.42 avg
969.71 avg
1706.88 mi
2378.10 mi
3449.10 avg
1210.68 avg
2372.41 avg

X

315-376
347-408
409-419
423-511
423-513
514-533
534-544
534-553
554-562
563-606
566-586
595-607

6940.20 avg
6765.80 avg
1346.85 avg
9013.93 avg
9300.75 avg
2050.03 mi
1300.60 mi
2400.63 avg
1100.18 mi
4835.07 avg
2424.22 mi
1592.73 mi

in-solution

missed cleavages

X
X

3
1

X
X

2
2

X
X
X
X
X
X

1
3
1

modification

X

X

2Met-ox

X
X
X

1Met-ox

2
1CAM

X

2

X
X
X

3
2

X

2CAM,
2Met-ox
2Met-ox
1CAM

X
X
X
X
X
X

X
X
X

1

X

1

X

3
1

a

1Met-ox

2CAM
1CAM

mi = observed as a monoisotopic mass. Avg = observed as an average mass, CAM =
carbamidomethyl cysteine.
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methods produce a 98% coverage of the 155 amino acid region of the hEAAT2 that is
particularly relevant to substrate binding (Figure 2.7).

2.4 Conclusions

In order to advance our understandings of the structure of hEAAT2 and facilitate
the design of selective inhibitors, functional hEAAT2 was expressed in HEK 293T cells
and purified in a single step using IMAC. Kinetic assays indicate the 6XHIS epitope
engineered into the N-terminus of the transporter did not affect its ability to bind and
transport substrates. Recombinant 6XHIS hEAAT2 expressed in a much higher level in
HEK 293T cells than other tested mammalian cell lines, provided us with sufficient
amounts of membrane material to use in the downstream IMAC purification and MS
characterization. From our expression system we were able to isolate about 300 µg
purified 6XHIS hEAAT2 protein in a single purification step. It is noteworthy that the
relatively low number of cells we started with (4 x 106) leaves plenty of room for scaling
up. Isolated 6XHIS hEAAT2 was digested with trypsin by both in-gel and in-solution
methods. In-gel digestion resulted in a 40% of sequence coverage of the whole protein
but lacked the coverage on the hypothesized substrate and competitive inhibitor binding
region. In-solution digestion with the addition of organic solvent greatly increased the
number of hydrophobic peptides identified from MALDI-TOF spectra. A 77% sequence
coverage was achieved and 91% of the amino acids in the binding site was identified
through in-solution method. It was interesting to find that glycosylation of the protein
seemed to prevent the identification of a large peptide from the binding pocket.
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Combining the in-gel and in-solution methods, 89% of the sequence coverage of the
protein was obtained with only TMD4 that remained unidentified in our study. The
successful identification of the peptides from the binding site offered us a template for the
future study of inhibitor-protein complexes and covalent modifications of the binding
pocket. Since the 6XHIS hEAAT2 expressed in HEK 293T cells is fully functional, the
relationship between the functional loss of the protein and the structural modifications to
the protein can be evaluated by MS analysis. Recently, a modified peptide in the binding
site was identified by MALDI-TOF after photo-inactivation of the 6XHIS hEAAT2 in the
presence of the 9-fluorenone containing hEAAT2 inhibitors (Chapter 2). In addition, the
expression system, protein solubilization, purification and MS methods we developed in
this work can easily be adapted to the structural analysis of other glutamate transporter
subtypes and other integral membrane proteins with similar topology.
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CHAPTER 3

FLUOROPHORE-ASSSITED LIGHT INACTIVATION OF HUMAN
EXCITATORY AMINO ACID TRANSPORTER 2 (EAAT2)

3.1 Introduction

3.1.1 Photochemical Tools in Studying Protein Structures
Long before tools such as X-ray crystallography and NMR became useful in
protein structure analysis, photochemical techniques represented one of the better
methods for studing biological processes at the molecular level. In these experiments,
photolysis of a probe containing a photoreactive group generates highly reactive
intermediates that can subsequently react with the spatially closest part of the
biomolecule. Modifications to the target protein are detectable by such methods as
immunoreactions, fluorescence or mass spectrometry. The site of the modification and
the functional changes on the modified protein provides us with information about its
structural features, as well as the interactions between the target and the small molecule
ligands. Depending upon the nature of the reactions involved in the protein modifications,
photochemical techniques can be generally divided between photoaffinity labeling and
photosensitization. It is also worth mentioning that although interest in photochemical
techniques decreased somewhat with the emergence of protein NMR and X-ray
crystallography, these approaches have become more popular as they often provide more
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information on protein dynamics of ligand binding when compared to the static images of
protein structure generated via crystallographic techniques.

3.1.1.1 Photoaffinity labeling
First proposed by Singh and Westheimer in 1962 (Singh et al., 1962),
photoaffinity labeling uses analogues bearing photophores that can be photo-activated
into reactive intermediates such as carbenes, nitrenes or biradicals. Commonly chosen
photophores include arylazides (Henry et al., 2002), diazirines (Smith and Knowles, 1973)
and diarylketones (Galardy et al., 1973) (Figure 3.1). The most commonly used
diarylketone is benzophenone. A fundamental difference between benzophenone groups
and other photophores is that biradicals are generated by 350 nm UV irradiation and the
reaction is reversible (Scheme 3.1). The long wavelength where the benzophenone group
is activated also makes these probes safer choices for biological systems (for review see
Prestwich et al., 1997). More recently, benzophenone-containing photoaffinity labels
have been used in probing the structures of the substance P (NK-1) receptor (Kage et al.,
1996), p-glycoprotein (Pleban et al., 2005) and the nicotinic acetylcholine receptor
(Garcia et al., 2007). In combination with mass spectrometry, a unique inhibitor-binding
domain was identified on HIV-1 integrase using benzophenone-linked coumarin IN
inhibitors (Al-Mawsawi et al., 2006). In addition to benzophenone itself, several other
closely related photophores have been successfully used as photoaffinity labels, including
acetophenones (Zor et al., 1995), benzoyl phenothiazines (Golinski et al., 1995) and
benzoyl indolines (Sun et al., 1994). The 9-fluorenone group provided another example
of benzophenone-like photophores. Fluorenone and benzophenone share similar
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Figure 3.1. Commonly-used photoaffinity labeling groups.
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Scheme 3.1. UV photo-activation of benzophenone group. Benzophenone can be
activated to its triplet state under 350 nm UV-A irradiation. Resulting biradical can
react with reactive carbon-hydrogen bond via hydrogen abstraction mechanism to
form benzophenone-protein conjugate.
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structural features, differing only by one carbon-carbon bond. The two also have similar
photochemical properties. A series of fluorenone-based compounds were shown to be
strong β2-adrenergic receptor antagonists (Wu and Ruoho, 2000) and used to directly
probe the catechol binding domain of the β2AR (Wu et al., 2001). Related compounds
were later confirmed to be vesicular monoamine transporter-2 (VMAT2) substrates and
used to identify the VMAT2 substrate binding pocket (Gopalakrishnan et al., 2007).
Coupling Boc-3-(3’-fluorenyl-9’-oxo)-L-alanine or 9-fluorenone-3-carboxylic acid with
the parathyroid hormone (PTH) molecule also yields potent agonists of human PTH1
receptor and the photo-crosslinking product generated receptor-ligand photo-conjugates
(Han et al., 2000).

3.1.1.2 Photosensitization
Similar to photoaffinity labeling, the reactive intermediates formed during the
process of photosensitization also represent the excited states of the photoactive
compounds. Following excitation, however, there are multiple pathways that can lead to
different reaction products as the group returns to its ground state. In most cases, oxygen
molecules are involved and lead to the oxidation of the target protein. In complex
biological systems, the photosensitization reactions often consist of competing
intermediates and pathways that can further complicate the manner in which the target
protein is oxidatively modified. These pathways are summarized in Figure 3.2. Oxygen
molecules can participate in one of two processes, referred to as Type I (O2-.) or Type II
(1O2). In most instances the Type II process dominates, because the reaction rate constant
is usually two orders of magnitude larger than that of the Type I path. In Type II
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Figure 3.2. Competing pathways and reactions of triplet state photosensitizer 3P.
Highly reactive 3P can undergo Type I reactions with O2, biomolecule M or ground
state photosensitizer P. Dominating Type I reaction is the O2 reaction that produces
superoxide anion. Type II reaction involves the energy transfer from 3P to O2 to
generate singlet oxygen. 3P can also be quenched to its ground state P.
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processes, 1O2 is generated from the excitation of ground state oxygen (3Σ). Of the two
excited states of oxygen, the first singlet state (1Δg) has an energy 22.6 kcal/mol above
the ground state, while the second excited state (1Σg)’s energy is 37.7 kcal/mol above 3Σ.
These energy differences lead to very large differences in the lifetime of the species in
aqueous solution (10-6-10-5 for 1Δg and 10-11 for 1Σg). When singlet oxygen-mediated
Type II photosensitization is the major route of protein photolysis, photooxidation most
often occurs at one or more of five amino acid residues: cysteine, histidine, methionine,
tryptophan and tyrosine. The reaction mechanisms and photooxidation products have
been reviewed in detail by Straight and Spikes (1979) and Davies, (2003). Typically,
photosensitization of proteins results in the degradation or oxidation of side chains of the
five residues mentioned above, although there have been isolated reports of other amino
acid side chains being damaged or producing protein fragmentation. The application of
external photosensitization to investigate protein structures is somewhat limited, because
the long lifetime of 1O2 and its diffusion radius (~300 Å, compared with 15 Å for triplet
biradical) often time results in nonspecific damage to protein side chains. Despite these
difficulties, there are numerous examples of successful photosensitization of protein
structures (Girotti et al., 1979; Verweij et al., 1981).

3.1.2 Chromophore-Assisted Laser Inactivation (CALI) and Fluorophore-Assisted Light
Inactivation (FALI)
A number of approaches have been developed to localize the generation of
reactive oxygen species (ROS) by photosensitization and thereby increase selectivity and
minimize nonspecific damage to the proteins. First reported in 1988, Jay et al. used 620
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nm laser beams to inactivate various enzymes in the presence of malachite green
isothiocyanate (MGITC)-coupled antibodies (Jay, 1988). The mechanism of this
inactivation, chromophore-assisted light inactivation (CALI), was first proposed to be
photothermal denaturation, but was later proven to be hydroxyl radical-mediated (Liao et
al., 1994). The maximal radius of damage was estimated to be 15 Å and the specificity
was fairly high (Liao et al., 1995). Replacing the malachite green in MGITC with
fluorescein resulted in an increase of two orders of magnitude in inactivation efficiency
(Buchstaller and Jay, 2000). This marked increase in inactivation efficiency allows
diffuse light sources to be used instead of a laser and led to the technique of fluorophoreassisted light inactivation (FALI). The mechanism of FALI was determined to be 1O2mediated and the half-maximal radius of the damage was estimated to be 30~40 Å (Beck
et al., 2002). Due to the requirements of using non-blocking antibodies in the original
versions of CALI and FALI, the approaches were not widely applicable to different
systems. Newer forms of FALI include genetically engineering a tetracysteine motif that
binds a fluorescein derivative 4’,5’-bis(1,3,2-dithioarsolan-2-yl)fluorescein (FIAsH). The
FIAsH-induced FALI has been used in the selective photoinactivation of synaptotagmin I
(Marek and Davis, 2002) and calcium regulatory protein calmodulin (CaM) (Yan et al.,
2006). In both studies, the photoinactivation was reported to be highly specific. Yan et
al. also characterized the resulting oxidation sites in CaM using trypsin digestion and LCMS. Methionine residues were found to be oxidized to methionine sulfoxides following
photolysis. Moreover, based on the peptide peak intensities, it was also concluded that
the photolysis modified histidine residues. The development of a fluorescein-conjugated
α-bungarotoxin (BTX) polypeptide and its use in the inactivation of metabotropic
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glutamate receptor 8a (mGluR8a) on rat sympathetic neurons provided another
interesting example of FALI applications (Guo et al., 2006). By engineering a 13 amino
acid BTX-binding domain into the N-terminus of mGluR8a, the investigators were able
to reduce mGluR8a-mediated inhibition of calcium currents (ICa) by 50% after photolysis.
However, unexpected observations of collateral damage to the GPCR-independent ICa
and natively expressed signaling pathways challenged the specificity of the BTX-FALI
system. Instead of developing FALI for individual proteins, Yogo et al. took a general
approach and reported a series of environment-sensitive photosensitizers that can be
activated by lipophilic environment in the protein’s binding pocket while remaining
inactivated in aqueous buffer (Yogo et al., 2008). This new strategy of designing proteinselective photoinactivators is likely to become a more general method of developing
photochemical probes for lipophilic pocket-containing proteins.

3.1.3 Design of Photochemical Probes for EAATs
Strategies for developing EAAT inhibitors has included both substituted
glutamate/aspartate analogues, such as (2S,4R)-4-methyl glutamate (4-MG), threo-3methylglutamate (T3MG), as well as conformational restricted glutamate/aspartate
analogues, such as dihydrokainate (DHK) and L-trans-2,4-pyrrolidine dicarboxylate (L2,4-PDC). Using the first approach, aromatic group-containing glutamate/aspartate
analogues, such as TBOA series (Shimamoto et al., 2000) and benzyl aspartate series
(Esslinger et al., 2005), proved to be potent EAAT inhibitors that also revealed the
presence of lipophilic binding domains on the transporter. The presence of such a
lipophilic pocket was also supported by actions of another series of very potent EAAT

62

inhibitors that linked aromatic groups to the distal COOH of aspartate (e.g. aryl
aspartylamides and aryl diaminopropionic acidss) (Greenfield et al., 2005). Interestingly,
the aromatic groups on these aspartate analogues included a number of potential
photoactivable moieties. In the present study, aspartate analogues were synthesized in
which benzophenone or 9-fluorenone groups were appended to its distal carboxyl group.
Our goal was to use the photoactive EAAT inhibitors as probes with which to modify and
identify binding domains on the transporter.
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3.2 Materials and Methods

3.2.1 Synthesis of Aryl Diaminopropionic Acids
General Remarks. Commercially available reagents were purchased from Aldrich
Chemical Co., Millwaukee, WI.

Analytical thin-layer chromatography (TLC) was

conducted on E. Merck aluminum-backed, 0.2 mm silica gel, TLC plates.

Flash

chromatography was preformed with Kieselgel 60, 230-400 mesh (Merck).

High-

resolution mass spectra (HRMS) were obtained by electrospray ionization (ESI) on a
Micromass LCT using caffeine as a mass standard at m/z 195.0882.

1

H and 13C NMR

were measured on a Varian VXR 400-NMR instrument (400 MHz and 100MHz
respectively).
Synthesis.
(1) General procedures for aryl diaminopropionic acids (1).
The target aryl diaminopropionic acids (1a and 1b) were prepared from N-Boc-3amino-L-alanine and the corresponding aromatic carboxylic acid, as illustrated in Figure
1.
The free carboxylic acid group on N-Boc-3-amino-L-alanine was first protected by
diphenyldiazomethane (Ph2C=N2, prepared from Miller, 1959) with one equivalent of ptoluenesulfonic acid in a mixture of acetonitrile and water. The reaction changed color
from purple to colorless in 1 h and the mixture was extracted with ethyl acetate and dried
over magnesium sulfate (MgSO4) to afford the benzyhydryl ester 3 (quantitative yield,
Baldwin, 1994): 1H NMR (CDCl3) δ 1.45 (9 H, s), 2.25 (2 H, br), 3.05-3.15 (2 H, m),
4.42 (l H, m), 5.82 (l H, br), 6.92 (l H, s), 7.30-7.48 (10 H, m); 13C (CDCl3) 28.3 (3x C),
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43.9, 56.0, 76.2, 78.0, 126.5 (2x C), 127.5 (4x C), 128.4 (4x C), 143.8 (2x C), 156.2,
171.5; MS (ESI) m/z 371.1970 (M+H+).
9-Fluorenone-2-carboxylic acid or 3-benzophenonecarboxylic acid was activated
by

BOP

reagent

hexafluorophosphate)

with

dimethylformamide (DMF).

((benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
one

equivalent

of

triethylamine

(Et3N)

in

N,N-

This activation process was monitored by TLC, which

showed the completion of the reaction after 4 h. Benzyhydryl ester 3 was added
afterwards and the resulting coupling reaction was monitored by TLC. After overnight
stirring, the reaction was complete. Water was poured into the reaction and the product
was extracted with diethyl ether. The organic layer was collected, dried, and the resulting
compound was further purified by flash chromatography to offer the coupling product 4.
α-N-tert-Butoxycarbonyl-β-fluorenonyl-2-carboxylic

acid

coupled

amino-L-

alanine benzhydryl ester (4a): 1H NMR (CDCl3) δ 1.45 (9 H, s), 2.25 (1 H, br), 3.85-3.97
(2 H, m), 4.62 (l H, m), 5.85 (l H, br), 6.88 (l H, s), 7.20-7.38 (10 H, m), 7.40-7.94 (7 H,
m); 13C (CDCl3) 28.2 (3x C), 39.9, 58.3, 76.1, 78.6, 126.5 (2x C), 126.9, 127.1 (4x C),
127.4, 128.2, 128.5, 128.6 (4x C), 129.9, 131.2, 134.3, 134.9, 139.3 (2x C), 140.2 (2x C),
143.3 (2x C), 158.4, 166.8, 169.5, 190.3; MS (ESI) m/z 577.14 (M+H+), 599.14 (M+Na+).
α-N-tert-Butoxycarbonyl-β-benzophenonecarboxylic acid coupled amino-Lalanine benzhydryl ester (4b): 1H NMR (CDCl3) δ 1.35 (9 H, s), 3.24 (1 H, br), 3.75-3.91
(2 H, m), 4.60 (l H, m), 5.96 (l H, br), 6.86 (l H, s), 7.22-7.29 (l0 H, m), 7.45 (3 H, m),
7.56 (1 H, t, J = 7.9 Hz), 7.74 (2 H, d, J = 6.7 Hz), 7.86 (2 H, d, J = 7.7 Hz), 8.10 (1 H, s);
13

C (CDCl3) 28.1 (3x C), 42.2, 54.3, 78.2, 79.9, 126.8 (2x C), 126.9, 127.8 (4x C), 127.9,
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128.3, 128.4, 128.5 (4x C), 130.1, 130.5, 130.8, 132.5, 139.3 (2x C), 137.7 (2x C), 139.4
(2x C), 155.9, 167.1, 169.7, 195.7; MS (ESI) m/z 579.22 (M+H+), 601.24 (M+Na+).
Compound 4 was deprotected by two equivalent of trifluoroacetic acid (TFA) in
dichloromethane (CH2Cl2). After overnight stirring, the mixture was dried on a rotatory
evaporator and the desired product (1) was precipitated under pH 4-5 aqueous solutions.
9-Fluorenonyl-2-diaminopropionic acid (1a): 1H NMR (D2O) δ 2.85 (2 H, br), 3.313.59 (2 H, m), 4.19 (l H, m), 2.25 (2 H, br), 6.84 (1 H, d, J = 7.7 Hz), 6.93 (3 H, m), 6.99
(1 H, s), 7.12 (1 H, t, J = 7.1 Hz), 7.31 (1 H, d, J = 8.1 Hz); MS (ESI) m/z 311.12
(M+H+), 333.11 (M+Na+).
benzophenonyl-3-diaminopropionic acid (1b): 1H NMR (CDCl3) δ 3.13 (2 H, br),
3.71-3.97 (2 H, m), 4.24 (l H, m), 7.04 (2 H, br), 7.48 (1 H, m), 7.57 (3 H, m), 7.77 (2 H,
d, J = 6.6 Hz), 8.00 (1 H, d, J = 7.8 Hz), 8.24 (1 H, d, J = 8.0 Hz), 8.43 (1 H, s); MS (ESI)
m/z 313.15 (M+H+), 335.16 (M+Na+).

3.2.2 Cell Culture and Transfection
C17.2 or HEK 293T cells (ATCC, Manassas, VA) between passages 10 and 20
were cultured at 37 °C in a humidified atmosphere containing 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 1 mM
sodium pyruvate, 0.1 mM nonessential amino acids solution, and 0.05% penicillin–
streptomycin (5000 units/ml) and gentamicin sulfate (0.05 mg/ml). Cells were seeded at
1 X 105 cells/well in 12-well plates for transporter activity experiments and 1.5 X 106
cells/dish in 100 mm2 dishes for membrane preparations. At 48 h after plating, cells were
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) or FuGENE
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Transfection Reagent (Roche, Indianapolis, IN) in a ratio of 2 µl of Lipofectamine to 2 µg
of purified plasmid DNA in accordance with the manufacturer's instructions.

3.2.3 Transporter Activity
Twenty four hours after transfection, near-confluent C17.2 or HEK 293T cells
were rinsed with a physiological buffer (138 mM NaCl, 11 mM d-glucose, 5.3 mM KCl,
0.4 mM KH2PO4, 0.3 mM Na2HPO4, 1.1 mM CaCl2, 0.7 mM MgSO4, 10 mM HEPES,
pH 7.4) and allowed to preincubate at 37 °C for 5 min. Uptake was initiated by replacing
the pre-incubation buffer with buffer containing 25 µM 3H-D-aspartate. Following a 5min incubation, the media was removed by rapid suction and the cells rinsed three times
with ice-cold buffer. The cells were dissolved in 0.4 N NaOH for 24 h and analyzed for
radioactivity by LSC and protein by the BCA (Pierce) method. Transport rates were
corrected for background, i.e., radiolabel accumulation at 4 °C. Initial studies confirmed
that uptake quantified in this manner was linear with time and protein levels and that
uptake in untransfected C17.2 or HEK 293T cells was indistinguishable from
background.

3.2.4 Light Sources and Illumination
Near-confluent C17.2 or HEK293T cells transfected with hEAAT DNA plasmids
were washed with assay buffer and replaced by assay buffer with photosensitizers and/or
inhibitors/substrates. Cells in dishes or 12-well plates were placed on ice and irradiated
by 350 nm light in a RPR-100 photolysis reactor (Southern New England Ultra Violet
Company, Branford, CT) equipped with 8 LZC-UVA lamps (Luzchem, Ottawa, ON) for
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1 h. Transporter activities were determined by radiolabeled assay immediately after UV
irradiation.

3.2.5 RNO Bleaching Assay
The generation of singlet oxygen by photosensitizers was determined by the
bleaching of N,N-dimethyl-4-nitrosoaniline (RNO) resulting from the reaction between
singlet oxygen and histidine (Kraljic and Mohsni, 1978). The RNO (50 µM) and Lhistidine (100 mM) were mixed with each photosensitizers in assay buffer followed by
UV irradiation under 350 nm lamps. The reaction was carried out in 96-well format and
the absorbance of the sample at 440 nm was measured in a Versamax microplate reader
(Molecular Devices, Sunnyvale, CA). Background absorbance was measured in the
absence of histidine and/or photosensitizers. Quantum yields of each photosensitizer were
calculated by comparing the bleaching rates of RNO with methylene blue.

3.2.6 In-Solution Trypsin Digestion
Aliquot of purified EAAT2 from His column was precipitated in 10% TCA at 4
°C for 30 min. The protein pellet was collected by centrifugation at 15,000g for 5 min.
The protein pellet was then washed with 1 ml of cold 1:1 ethanol:ether (v:v) solution 3
times. The washed pellet was briefly air-dried and resuspended in 20 mM ammonium
bicarbonate buffer, pH 8.0 (AMBIC). PNGase F (from Elizabethkingia meningoseptica,
Sigma-Aldrich, St. Louis, MO) was added at the ratio of 50 units per mg of protein. The
solution was mixed and incubated at 37 °C for 1 h. This enzyme recognizes the Nglycosylation sites of glycoproteins and cleaves the linkage between Asn and
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carbohydrate chain (Tarentino and Plummer, 1994). Sequence grade trypsin (Promega,
Madison, WI) was added at a 1:20 ratio, and digestion was allowed to proceed at 37 °C
for 20 h. Tryptic peptides were analyzed from the digest solution.

3.2.7 Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectroscopy
MALDI-TOF analysis was performed on a Voyager DE PRO (Applied
Biosystems, Foster City, CA). An aliquot of sample was mixed with an equal volume of
CHCA matrix solution in 50% acetonitrile and 0.1% TFA, and 1 µl was spotted onto the
target plate. A Bruker peptide standard was used for calibration. For average masses
obtained in linear mode, mass accuracy was set at 200 ppm; for monoisotopic masses
obtained in reflectron mode, mass accuracy was set at 50 ppm. Masses were searched
against the NCBI protein database or an EAAT database using Mascot
(www.matrixscience.com). Modifications for partial methionine oxidation were included.
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3.3 Results

3.3.1 Synthesis of Aryl Diaminopropionic Acids
The steps involved in the synthesis of β-2-Caboxy-fluorenonyl-diaminopropionic
acid (β-2-CFoDA) and β-2-Caboxy-benzophenonyl-diaminopropionic acid (β-2-CBoDA)
are outlined in Scheme 3.2. Our initial attempts to follow the procedures previously
reported by Greenfield et al. did not produce an acceptable yield of the desired products.
Therefore, a new strategy using benzotriazole-1-yl-oxy-tris-(dimethylamino)phosphonium hexafluorophosphate (BOP) as the coupling reagent was employed. The
protection of the free carboxylic group on N-Boc-3-amino-L-alanine was optimized using
diphenyldiazomethane (Ph2C=N2, prepared from Miller et al., 1959). The coupling
product was purified by flash chromatography followed by TFA treatment to remove
protection groups. Final product was precipitated from aqueous solution by adjusting pH
to 4-5. Compared with the coupling reagents reported by Greenfield et al. (Nhydroxysuccinimide and DIC (N,N’-diisopropylcarbodiimide)), our method had a higher
yield (~27%), purity and offered more flexibility in synthesizing other analogues bearing
similar scaffolds. The aryl aspartylamides characterized in this chapter were synthesized
by Brent Lyda in a collaborative project between the Bridges and Esslinger labs (Bridges
et al., 2008).

3.3.2 Pharmacological Characterization of β-2-CFoDA at EAATs
A series of aryl aspartylamides and diaminopropionic acidss, that included β-2CFoDA, were initially screened at 10 µM and 100 µM for the ability to inhibit the uptake
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Scheme 3.2. Synthesis of aryl diaminopropionic acids (1a and 1b). Reagents and
conditions: (i) Ph2CN2, p-CH3C6H4SO3H, in CH3CN/H2O (ii) Ar-COOH (3a/3b), BOP;
Et3N in DMF (iii) TFA in CH2Cl2 and HCl.
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of [3H]-D-aspartate (25 µM) into C17.2 cells expressing EAAT1, EAAT2 or EAAT3.
Transporter assays were carried out as described in Methods, with rates appropriately
corrected for nonspecific background (4 °C) and normalized for protein content. The
data are reported in Table 3.1 as the mean % of control (±SEM) measured in the absence
of inhibitors. Thus, the lower the values the greater the level of inhibition. Among the
analogues examined, β-2-CFoDA, β-2-FoAA and β-2-FAA proved to be the most potent
inhibitors at all EAAT subtypes. Essentially all three compounds were able to inhibit
almost 100% of D-aspartate uptake when incubated in the assay at 100 µM. In contrast,
β-2-PAA, β-2-BPAA, β-2-DCPAA, β-2-NAA, and β-2-CBoDA showed only low levels
of inhibitory activity at EAAT1 and EAAT2. These analogues did exhibit modest actions
against EAAT3 at 100 µM, with little inhibition observed when the concentration was
decreased to 10 µM. More detailed, dose-response experiments were conducted on β-2CFoDA, β-2-FoAA and β-2-FAA to examine the concentration-dependence with which
they inhibited the EAATs. Results of these assays were reported in Table 3.1 as the
concentrations at which D-aspartate uptake was inhibited by 50% (IC50). Representative
plots for β-2-CFoDA IC50 plots are shown in Figure 3.3. The data showed that all three
compounds are very potent inhibitors of each of the three EAAT subtypes, with IC50
values in the low micromolar to nanomolar range. It is also noteworthy that although
there is more than an order of magnitude in the differences in inhibitory potencies of
analogues, the rank of potencies at each EAAT subtypes is well preserved (i.e. EAAT3 >
EAAT1 > EAAT2).
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Table 3.1. Pharmacological screening of aryl diaminopropionic acids and aryl
aspartylamides on EAAT1-3. All screening was performed at two inhibitor
concentrations: 100 uM and 10 uM. Additional concentrations were used to calculate
the IC50 values for selective compounds.
Abbreviation

EAAT1
100
10
uM
uM

Structure

EAAT2
100
10 uM
uM

EAAT3
100
10 uM
uM

O

β-2-CFoDA

O

O

HO

N
H

NH2

IC50 = 1.44±0.31
uM (3)

IC50 = 20.3±2.2
uM (3)

IC50 = 0.09±0.01
uM (3)

IC50 = 0.26±0.01
uM (3)

IC50 = 6.2±0.5 uM
(3)

IC50 = 0.25±0.03
uM (3)

IC50 =
0.44±0.001 uM
(2)

IC50 = 0.61±0.17
uM (5)

IC50 = 0.03±0.02
uM (4)

O

β-2-FoAA

O

H
N

HO
NH2 O

O

β-2-FAA

NH

HO
NH2 O

O

β-2-BPAA

NH

HO
NH2 O
O

β-2-PAA

NH

HO
NH2 O

O

β-2-DCPAA

Cl
NH

HO

Cl

NH2 O

89±6(3
)

80±9(3
)

82±7(3)

82±2(3)

65±3(3)

83±4(3)

74±12(
3)

94±9(3
)

72±4(2)

102±4(
2)

41±6(3)

80±10(
3)

80±5(3
)

92±11(
3)

79±5(3)

83±3(3)

43±1(3)

73±9(3)

50±11(
3)

75±8(3
)

78±5(3)

88±5(3)

7±1(3)

45±3(3)

68±10(
3)

91±9(3
)

63±13(
3)

93±3(3)

35±8(4)

84±3(4)

51±7(3
)

93±4(3
)

52±7(3)

87±4(3)

25±5(2)

77±9(3)

102 ±
2(3)

-

-

109 ±
4(3)

-

O

−

O

NH2

HO

H
N

O
O

β-2-NAA

NH

HO
NH2 O

O

β-2-CBoDA

O

O

HO
NH2

O

9F2C

N
H

O
OH

73

94 ±
5(3)

Figure 3.3. Dose-response curves showing competitive inhibitory activity of β-2carboxy-fluorenonyl diaminopropionic acid (β-2-CFoDA or RB362) on EAAT1-3.
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Our results indicated that coupling fluorene or 9-fluorenone groups with an
aspartyl amide or a diaminopropionic acids produced very potent EAAT inhibitors with
IC50 vlaues comparable to some of the most potent EAAT inhibitors identified to date
(TFB-TBOA, IC50 = 2-20 nM, Shimamoto et al., 2002). Compared with the IC50 values
of the same compounds reported in Greenfield et al. (2005), our assays yielded slightly
higher inhibition potencies probably due to differences in cell line and assay conditions.
Replacing the fluorene or 9-fluorenone groups with phenyl, biphenyl, napthyl or
dicholorophenyl groups resulted in an almost complete loss of inhibitory activity. More
surprisingly, coupling diaminopropionic acids with benzophenone, a group that only
differs by one carbon-carbon bond from the 9-fluorenone group, markedly decreased
inhibitory activity. Considering that both groups are highly conjugated aromatic systems,
the orientation and electron densities should be similar. The dramatic differences in
activity thus suggested high specificity interactions between the binding pocket of the
proteins and the fluorene/9-fluorenone groups. We did notice the slight drop in potency
from β-2-FAA to β-2-FoAA to β-2-CFoDA, which may be attributed to the addition of
an extra carbonyl group on 9-fluorenones. Based on the above observations, we believe
there is a lipophilic pocket in the EAAT proteins that can accommodate large aromatic
ring systems (fluorene, 9-fluorenone) and the molecular recognition mechanism is highly
specific. Among all the aromatic groups, fluorene seems to have the highest affinity to
the lipophilic pocket.
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3.3.3 Photo-Inactivation of EAATs by β-2-CFoDA
It has been known for a long time that 9-fluorenone groups can be activated by
UV light to produce triplet state biradicals. The highly reactive fluorenone biradicals are
involved in numerous photosensitizing processes and are also capable of generating
additional secondary reactive oxygen species (ROS). If proteins are present in the system
while these reactive intermediates are being generated, they tend to serve as quenchers or
energy acceptors to the intermediates by means of photoreactions. The study of
photoreactions between proteins and photosensitizer-induced reactive intermediates
provides a good strategy to probe protein structure. More importantly, if the reactions
occur in specific regions of proteins, such as at an enzyme-substrate interface,
investigating the photochemical interactions could provide greater insights into substrate
and inhibitor binding at the molecular level. Among the EAAT inhibitors we synthesized
and characterized, β-2-CFoDA and β-2-FoAA possess 9-fluorenone groups that have the
potential to be photo-activated and consequently used as photoaffinity probes for the
EAATs.
C17.2 Cells expressing EAAT1, EAAT2 or EAAT3 were incubated in
physiological buffer with compounds bearing 9-fluorenone groups while being
illuminated by 350 nm UV lights in a UV-photolysis reactor. Immediately following UV
exposure, the cells were rinsed to remove the inhibitors and then assessed for uptake
activity using the standard radiolabeled flux assay. In initial experiments we found that
incubation with either β-2-CFoDA or β-2-FoAA in presence of UV illumination led to a
decreased level of uptake. To establish control levels of activity, cells incubated with the
inhibitors were placed in the UV reactor covered by aluminum foil. Additional
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experiments also determined that 350 nm UV illumination did not cause any apparent cell
death nor significant nonspecific transporter activity losses in the absence of the
photosensitizers. In contrast, neither 300 nm nor diffuse light source (desk lamp) could
induce a significant activity loss, while 250 nm illumination greatly reduced cell viability
and almost all transporter activity after 15 min.
To further investigate the nature of the 350 nm UV-dependent, 9-fluorenonemediated inactivation of the EAATs, we performed a series of control experiments. We
observed that loss in the EAAT activity was irreversible and did not recover up to 30 min
after the cells were removed from the photolysis reactor. Hence we deemed this
inhibition to be photo-inactivation. The photo-inactivation was found to be positively
correlated to both the times of illumination and concentrations of the inhibitor. The
concentration dependence with which β-2-CFoDA and β-2-FoAA inactivated EAAT2 is
illustrated in Figure 3.4. Of the two inhibitors, β-2-CFoDA produced a significantly
greater levels of inactivation (1 h UV exposure) at all concentrations tested.
Interestingly, β-2-FoAA did not induce significant EAAT2 photo-inactivation until its
concentration reached 250 µM. The time dependence of EAAT2 inactivation by β-2CFoDA (100 µM) is illustrated in Figure 3.5. We observed the photo-inactivation
became significant after 45 min of illumination. After 120 min, EAAT2 activity dropped
down to a level that was indistinguishable from background nonspecific activity (Figure
3.5). A 350 nm light sources and 60 min illumination time was used in the remainder
studies unless mentioned otherwise.
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Figure 3.4. EAAT2 activity is irreversibly inhibited by UV-A illumination in the
presence of 9-fluorenone-containing compounds. C17.2 cells expression human
EAAT2 were illuminated by 350 nm light in the presence of 9F2C, β-2-CFoDA
(RB362) or β-2-FoAA (RB363) for 1 h before their activity being measured using
radiolabeled uptake assay. Data represents the mean ± SD for three experiments.
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Figure 3.5. Time-dependent photo-inactivation of EAAT2 by β-2-CFoDA. EAAT2expressing C17.2 cells were illuminated by 350 nm light for various times in the
presence of 100 µM RB362. Transporter activity was measured after UV illumination.
Data represent the mean ± SD for three experiments.
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As an additional control we carried out a parallel series of experiments, using the
free photophore-9F2C. Uptake studies confirmed that 9F2C is not a competitive inhibitor
of any of the EAATs (Table 3.1). To our surprise, 9F2C also led to the inactivation of
EAAT2 in the presence of 350 nm UV illumination. As shown in Figure 3.4, 9F2C
proved to be the most potent inactivator of the three compounds. The fact that 9F2C does
not bind to the EAAT substrate site (i.e., it is not a competitive inhibitor), suggested that
it, as well as the other 9-fluorenone-containing ligands, were not acting as direct
photoaffinity labels, but inactivating the transporters through an indirect mechanism.

3.3.4 Photosensitizer-Induced EAAT Photo-Inactivation is via Singlet Oxygen Mechanism
As previously discussed, the action of 9F2C suggested that the 9-fluorenone
groups were likely inactivating the EAATs indirectly via reactive intermediates. In the
presence of photosensitizers and oxygen, UV illumination produces a variety of reactive
intermediate species that can participate in different types of photoreactions. When
proteins are also introduced into the system, the reaction mechanism becomes even more
complicated, with the possible reaction pathway differs on a case-by-case basis. It has
been known for a long time that the 9-fluorenone groups are readily excited to its triplet
biradical state by 350 nm UV light (Galardy et al., 1973). The photo-inactivation of the
EAATs we observed was also most effective at 350 nm UV illumination. A series of
experiments was carried out to elucidate the mechanism of inactivation. First, we found
that EAAT1, EAAT2, and EAAT3, were all effectively photo-inactivated by all three of
the 9-fluorenone-bearing compounds (Figure 3.6). Although each subtype exhibited a
different rate of transport in our expression system, the relative decrease in uptake
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Figure 3.6. Compounds containing 9-fluorenone groups inactivate EAAT activity
under 350 nm UV illumination. β-2-CFoDA- and 9F2C- induced photo-inactivation
effects were observed in three EAAT subtypes (EAAT1, EAAT2 and EAAT3. UV
illumination time was 1 h. Concentrations of β-2-CFoDA and 9F2C are both 100 µM.
**p < 0.01; ***p < 0.001.
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activity caused a photo-inactivation remained roughly the same. In this respect the ability
of the analogues to inactivate the EAATs did not correlate with their respective
pharmacological profiles. Thus, β-2-FoAA was more potent as a competitive inhibitor
than as an inactivator when compare to β-2-CFoDA. This suggested that inactivation
was not dependent solely upon the ability of the analogues to bind to the substrate site on
the transporters. Once bound, variables such as the orientation and proximity of the
photophore to target residues probably have a significant influence on the efficiency of
inactivation. This was even more the case for 9F2C which, based on competitive studies,
does not even bind to the substrate site on the transporter.
Greater insight into the mechanism came with the demonstration that the
inclusion of 5 mM NaN3 in the reaction buffer effectively prevented the photoinactivation in all EAAT subtypes induced by both β-2-CFoDA (Figure 3.7A) and 9F2C
(Figure 3.7B). Azide ion is a well known singlet oxygen (1O2) physical quencher and the
protective effects offered by NaN3 strongly indicate the involvement of 1O2 in the photoinactivation processes. To determine if 1O2 is indeed the major intermediate species that
caused the photo-inactivation, we carried out a series of studies to explore the
possibilities of the involvement of 1O2 and other ROS. To compare with the protective
effects of NaN3, we selected two ROS scavengers to test the potential contribution of
hydroxyl free radical, superoxide anion and H2O2. Concentrations of 50 mM D-mannitol
(Melinn and McLaughlin, 1986) and 1 mM glutathione (GSH, Devasagayam et al., 1991)
were included in the reaction buffer during the photo-inactivation. Our results show that
neither mannitol nor GSH provided significant protection against the photo-inactivation
of EAAT2 by either β-2-CFoDA or 9F2C (Figure 3.7). Similar results were also
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Figure 3.7. Photosensitizer-induced EAAT2 photo-inactivation is blocked by singlet
oxygen quencher NaN3, but not by ROS scavengers D-mannitol or GSH. (A) EAAT2
activity measured after 1 h UV illumination at the following conditions: (1) control;
(2) β-2-CFoDA (100 µM); (3) β-2-CFoDA (100 µM) + NaN3 (5 mM); (4) β-2CFoDA (100 µM) + D-mannitol (50 mM); (5) β-2-CFoDA (100 µM) + GSH (1 mM).
**p < 0.01. (B) EAAT2 activity measured after 1 h UV illumination at the following
conditions: (1) control; (2) β-2-FoAA (100 µM); (3) β-2-FoAA (100 µM) + NaN3 (5
mM); (4) β-2-FoAA (100 µM) + D-mannitol (50 mM); (5) β-2-FoAA (100 µM) +
GSH (1 mM). **p < 0.01.
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observed in EAAT1 and EAAT3 photo-inactivation experiments (data not shown). These
findings are consistent with the conclusions that 1O2 played a much more important role
than hyhdroxyl radicals, superoxide anions and H2O2. As a second strategy to confirm
that the inactivation was 1O2-mediated, assays were designed to exploit the lifetime
variations of 1O2 in different solvents. In D2O, the lifetime of 1O2 is about 20 µs, which
is about 10 times longer than that in H2O. Measurements of reaction rate differences in
these two solvents are often used to support the direct involvement of 1O2 in
photochemical processes. In our EAAT2 photo-inactivation studies, we replaced H2O
with D2O in the reaction buffer and noticed an increased level of inactivation level
compared to H2O (Figure 3.8B). The percentages of decrease in EAAT2 activity resulted
from both β-2-CFoDA- and 9F2C-mediated photo-inactivation in the D2O groups were
determined to be statistically significant from those in the H2O groups. We also noticed
that the control EAAT2 activity is slightly lower in the D2O group, indicating that
nonspecific (non-photosensitizer-induced) 1O2 species inhibited EAAT2 activity in D2O
buffer while they normally would be depleted in the H2O buffer. These observations
prompted us to propose a photosensitizer-induced EAAT photo-inactivation pathway in
which 1O2 is the key intermediate directly reacts with the proteins.
Having established a 1O2-mediated mechanism for the EAAT photo-inactivation,
we sought to determine if this effect is specific to the 9-fluorenone groups. As part of
this effort we quantified the rates of 1O2 production by all three 9-fluorenone-bearing
photosensitizers in our reaction solvent system and compared it with known 1O2generator using histidine and p-nitrosodimethylaniline (RNO) (Kraljic and Mohsni,
1978). In this RNO bleaching assay analysis, the loss of RNO absorption at 440 nm
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Figure 3.8. Photosensitizer-induced EAAT2 photo-inactivation is via singlet oxygen
(1O2) mechanism. (A) 1O2 quantum yields of photosensitizers measured by RNO
bleaching assay. Slopes of the linear curves represent the 1O2 generation rates under
our reaction conditions. Concentrations of photosensitizers: 9F2C (100 µM), β-2CFoDA (100 µM), β-2-FoAA (100 µM), Methylene blue (10 µM). (B) EAAT2
photo-inactivation levels are affected by 1O2 lifetimes (10 times longer in D2O than in
H2O). β-2-CFoDA- and 9F2C-induced photo-inactivation experiments were
conducted in H2O and D2O buffers. EAAT2 activity (as % of control levels) was
measured after 1 h UV illumination. Concentrations of photosensitizers: 9F2C (100
µM), β-2-CFoDA (100 µM). **p < 0.01.
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produced by the reaction product of histidine and 1O2 is plotted against time. The
resulting slope represents the rate of 1O2 generation, or quantum yield (ΦΔ). Under our
illumination conditions we found both 9F2C and β-2-CFoDA are efficient 1O2 producers
in our aqueous reaction buffer, while β-2-FoAA is a weaker 1O2 generator (Figure 3.8A).
By comparing ΦΔ of each photosensitizer with that of a known water-solubile
photosensitizer, methylene blue (MB, 0.52, Kochevar and Redmond, 2000), the ΦΔs for
9F2C, β-2-CFoDA, β-2-FoAA at 100 µM were determined to be 0.598 ± 0.0095, 0.519 ±
0.012 and 0.34 ± 0.014, respectively. The 1O2 quantum yields agreed quite well with the
levels of photo-inactivation we observed with each photosensitizers. The differences in
the ability of these photosensitizers to generate 1O2 can be attributed to the electron
donating/withdrawing groups attached to the 9-fluorenone groups. The secondary amine
group in β-2-FoAA likely destabilizes the triplet intermediate, while carbonyl groups (in
9F2C and β-2-CFoDA) stabilize the biradical. The difference in 1O2 quantum yield
provide an explanation as to why higher concentrations of β-2-FoAA were required to
induce similar levels of EAAT inhibition as 9F2C and β-2-CFoDA. The results are also
consistent with 9-fluorenone triplet biradical being the initial intermediate species and
that the production of the biradical may be the rate-limiting step of this complex reaction
system. Because the ΦΔ of β-2-CFoDA (0.519) is very close to that of MB in our
experimental conditions, we were curious as to what level of photo-inactivation MB
would induce in the EAAT proteins. In contrast to 9F2C, co-incubation of MB failed to
induce the photo-inactivation of any EAAT subtypes (Figure 3.9). These results
suggested that although β-2-CFoDA and MB produced 1O2 at approximately the same
rates, 1O2 species generated by MB were unable to reach and react with the residues on
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Figure 3.9. Methylene blue (MB) does not photo-inactivate either EAAT subtypes.
The singlet oxygen quantum yield of MB is similar to that of 9F2C/β-2-CFoDA
(RB362). However, UV illumination of transporter-expression cells in the presence of
MB did not cause a significant decrease of transporter activities. Data represent the
mean ± SD for three experiments.
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EAAT2 that would lead to inactivation. In turn this suggests that both β-2-CFoDA and
9F2C were able to interact with the EAATs, in such a manner as to be positioned close
enough and long enough for the resulting 1O2 to inactivate the transporter.

3.3.5 EAAT2 Inhibitors Protect Against β-2-CFoDA-Induced Photo-Inactivation
Our results indicate that the interactions between EAATs and 9-fluorenone groups
are highly specific and the sites where 1O2 being generated are very close to the protein
domains on the EAATs. To address this, we introduced various EAAT2 inhibitors and
substrates into our photo-inactivation assays to see if any of these ligands could protect
against inactivation. The inhibitors and substrates chosen were: L-glutamate, TBOA, and
β-2-FAA. L-Glutamate is the endogenous substrate of EAATs and is efficiently
transported into the cells. In contrast, TBOA and β-2-FAA are both non-transportable
EAAT2 inhibitors. It is thought that the lipophilic groups present on these analogues
serve to increase potency when they bind, as well as render their non-substrate properties.
In particular, β-2-FAA is a very potent inhibitor that is structurally quite similar to β-2CFoDA. These compounds were incubated with either 9F2C or β-2-CFoDA during the
photo-inactivation reactions. All drug solutions were then washed off before transporter
activity was evaluated. The concentrations of the compounds (L-glutamate: 100 µM,
TBOA: 7.4 µM, β-2-FAA: 1 µM) were calculated to give approximately the same
percentage of occupancy to the proteins based on their IC50 or Ki values. We observed
very different results from 9F2C- and β-2-CFoDA- induced photo-inactivation
experiments. The β-2-CFoDA-induced photo-inactivation was effectively prevented by
the co-incubation of β-2-FAA, but not by TBOA or L-glutamate (Figure 3.10A). In
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Figure 3.10. β-2-CFoDA- and 9F2C- induced EAAT2 photo-inactivation has
different levels of specificity suggested by protective effects of EAAT2 inhibitors.
(A) EAAT2 activity was measured after 30 min UV illumination at the following
conditions: (1) control; (2) β-2-CFoDA (100 µM); (3) β-2-CFoDA (100 µM) + β-2FAA (1 µM); (4) β-2-CFoDA (100 µM) + TBOA (7.4 µM); (5) β-2-CFoDA (100 µM)
+ L-glutamate (100 µM). (B) EAAT2 activity was measured after 30 min UV
illumination at the following conditions: (1) control; (2) 9F2C (100 µM); (3) 9F2C
(100 µM) + β-2-FAA (1 µM); (4) 9F2C (100 µM) + TBOA (7.4 µM); (5) 9F2C (100
µM) + L-glutamate (100 µM). *p < 0.05.
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contrast, none of the inhibitors or substrates was able to protect the transporters from
being photo-inactivated by 9F2C (Figure 3.10B). The protective actions of β-2-FAA is
consistent with the conclusion that β-2-CFoDA was bound in the substrate site when it
inactivated the transporter. The inability of either L-glutamate or TBOA to protect may
reflect the fact that their association and dissociation rates were not slow enough to
prevent β-2-CFoDA to bind and inactivate the transporter during the 60 min incubation.
β-2-FAA, on the other hand, has been found to exhibit very long dissociation rates
(Bridges et al., 2008; Kavanaugh et al., 2008). However, the binding and unbinding of β2-FAA with EAAT2 did not seem to affect the photo-inactivation efficiency induced by
9F2C. This would suggest a possible second inactivation site or a different binding
orientation by 9F2C from the binding of β-2-CFoDA. From these observations we
hypothesize: i) EAAT2 proteins were photo-inactivated by 9F2C and β-2-CFoDA both
via a 1O2-mediated mechanism but the inactivation site(s) may be different; ii) The
EAAT2 lipophilic interaction site(s) with β-2-CFoDA and β-2-FAA is different from the
domains that interact with TBOA, which is HP2 as illustrated by the GltPh crystal
structure (Yernool et al., 2004; Boudker et al., 2007).

3.3.6 β-2-CFoDA-Induced Photo-Inactivation is Caused by Oxidation of a Binding
Domain Peptide
In the final set of experiments we used mass spectrometric (MS) tools to locate the site(s)
at which the 1O2 reacted with and inactivated EAAT2. As discussed in Chapter 2 we
previously developed a high-yield, functional expression and purification protocol for
his-tagged EAAT2 (Ye et al., 2009). Our trypsin digestion method and MALDI MS
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characterization offered 89% sequence coverage of the EAAT2. In particular, this
protocol resulted in near-complete coverage of the regions of EAAT2 postulated to
participate in substrate binding. In this study we took advantage of the EAAT2 MS
peptide fingerprint we generated and attempted to idenitify peptides that were modified
through photo-inactivation. In-solution trypsin digestion was performed on both the
control samples and the EAAT2 proteins that had been photo-inactivated by either β-2CFoDA or 9F2C. MS characterization was conducted on peptide fragments from the
digestions by MALDI-TOF. Comparison between the MS peptide fingerprint generated
from 9F2C-inactivated EAAT2 samples were indistinguishable from control samples in
the range of our mass scans. It is also noteworthy that protein cross-linking is often
associated with photosensitization and MS detection and analysis of resulting high
molecular weight peptides are difficult. However, in the case of β-2-CFoDA-induced
EAAT2 photo-inactivation, a large peptide fragment was consistently found to have a
higher m/z value from the photo-inactivated sample than from the control sample. The
centroid m/z values for this peptide from control samples were 9013 ± 2 in 10
independent experiments. In the EAAT2 samples photo-inactivated by β-2-CFoDA, the
same peptide had centroid m/z values of 9040 ± 3 (6 independent experiments). The
primary sequence of the human EAAT2 and representative MS spectra are shown in
Figure 3.11. In this particular example, a mass shift of 16 amu was observed for the
peptide indicating a single oxygen atom addition. In our peptide assignment, this peptide
corresponds to amino acid residues 388-476 in EAAT2, covering TM7, HP2 and part of
TM8 regions of the protein based on the homology model of EAAT2 generated from
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Figure 3.11. MALDI MS analysis reveals an oxidized peptide in β-2-CFoDA-induced
EAAT2 photo-inactivation. (A) Amino acid sequence of human EAAT2. The
transmembrane domains (TMs) are marked in bold, the hairpin loops (HPs) are
marked in italic. A tryptic peptide fragment (underlined) was found to be oxidized
during the β-2-CFoDA-induced EAAT2 photo-inactivation processes. (B) MALDI
MS spectrum of in-solution trypsin digest from control samples. Peptide assignments
and average masses are labeled. (C) A representative MALDI MS spectrum of photoinactivated EAAT2 trypsin digest sample (β-2-CFoDA, 200 mM; illumination time, 1
h). Arrowheads designate a mass shift of 16 amu by the underlined peptide in panel
(A), corresponding to oxidation product.
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GltPh structures. The increased peptide mass suggested possible oxidations of this
peptide at one or more residues via 1O2. Inspection of this peptide revealed the presence
of a tyrosine, a tryptophan and three methionine groups that are considered primary
targets for 1O2-mediated oxidation.

3.4 Discussion

High-affinity, Na+-dependent glutamate transporters play an essential role in fast
synaptic neurotransmission, regulating extracellular glutamate concentrations, synaptic
plasticity, learning and memory (Tzingounis and Wadiche, 2007). Our current
understanding of the tertiary and quaternary structures of this family of integral
membrane is based upon cumulative data from a number of approaches, including
cysteine surface scanning (Slotboom et al., 2001; Seal and Amara, 1998; Grunewald et
al., 1998), the crystallizations of prokaryotic EAAT homolog (Yernool et al., 2004;
Boudker et al., 2007), mass spectrometric characterization (Chapter 2), fluorescent
labeling (Larsson et al., 2004; Koch et al., 2007), inter-subunit interactions and
oligomeric structures (Raunser et al., 2006). With the exception of the crystallographic
studies of GltPh, experiments directly examine the interaction of EAAT domains with
different substrates and inhibitors has been limited. The identification of ligand-protein
interactions is a key step towards a full understanding of the transporting mechanism. In
this study, we took advantage of the established MS peptide fingerprint (Chapter 2), the
reports of aryl aspartylamdies and aryl diaminopropionic acids as potent EAAT inhibitors
(Greenfield et al., 2005), and the photoreactivity of 9-fluorenone groups, and used a
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combination of pharmacological, photochemical and mass spectrometric tools to provide
evidence of the inhibitor-EAAT interactions.
We synthesized the 9-fluorenonyl derivatives of both the aspartylamide and
diaminopropionic acids templates and demonstrated that both led to an irreversible loss of
activity by all 3 EAATs. This inactivation was dependent upon 350 nm UV illumination
and the needed exposure times were consistent with other studies using biaryl ketone
groups (Han et al., 2000; Garcia et al., 2007). The photoactive ligand also inactivated the
EAATs in a concentration dependent manner. Understanding both the mechanism and
specificity of the photoreactive ligand was critical to evaluate their utility as probes of the
EAAT binding domains.

3.4.1 9-Fluorenone-Mediated EAAT Inactivation is via Singlet Oxygen Mechanism
Given the functional significance of the EAATs, it is not surprising that
considerable efforts have been focused on the development of potent and selective
inhibitors of these transporters. Recent studies have identified a series of aryl
aspartylamides and aryl diaminopropionic acidss as being among the most potent EAAT
blockers yet identified, exhibiting IC50 values in the nanomolar range (Dunlop and
Butera, 2006). An examination of these analogues revealed that the aryl ketones
including 9-fluorenone groups are well-known for their photoreactivity. For example,
benzophenone-bearing inhibitors have been synthesized and tested their photoaffinity in
various studies (Pleban et al., 2005; Garcia et al., 2007). In combination with MS, a
unique HIV-1 integrase inhibitor-binding domain was identified by using benzophenonelinked coumarin integrase inhibitor (Al-Mawsawi et al., 2006). The long excitation
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wavelength (~350 nm) induces minimal damage to the cells and has made biaryl ketones
the photophore of choice for in vitro studies (Prestwich et al., 1997). Sharing common
structural features with benzophenone, 9-fluorenone exhibits similar photochemical
properties and has been used in several studies, such as the human parathyroid hormone 1
receptor ligand binding domain (Han et al., 2000), the catechol binding domain of the β2adrenergic receptor (Wu et al., 2001), and the substrate binding pocket of the vesicular
monoamine transporter 2 (Gopalakrishnan et al., 2007).
The combination of photoreactive properties of the 9-fluorenone and the high
affinity of the inhibitors suggested the compounds could be used as ligand probes to
identify domains on the EAATs that participate in substrate binding. UV illumination of
biaryl ketone groups can potentially inactivate proteins through a number of mechanisms,
including both direct and indirect pathways. In our studies, the possibility of direct crosslinking between 9-fluorenone biradical was ruled out by the inactivation caused by 9F2C,
a non-inhibitor on the EAATs because the short lifetime of the biradical hence the short
reaction radius (< 5 Å). The possible involvement of ROS radicals was also excluded by
the minimal protection effects displayed by GSH (against superoxide anion and H2O2)
and D-mannitol (against hydroxyl radical). It is interesting in this regard that Volterra et
al. reported, in cortical glial cultures, glutamate uptake is inhibited by reactive oxygen
species such as superoxide anion, hydroxyl radical and H2O2 (Volterra et al., 1994).
They also found that the presence of scavengers such as GSH blocked almost all the
inhibition. We found that the best protection from the UV-dependent, 9-fluorenonemediated inactivation was NaN3. The azide ion is a strong physical quencher of 1O2 and
is often used to show the involvement of the 1O2 in the photoreactions (Li et al., 2001). A
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1

O2-mediated inactivation pathway is also consistent with our demonstration that even

greater losses of activity were observed in the D2O reaction buffer. In the original
mechanistic studies of FALI, D2O experiments provided direct evidence of 1O2’s role as
predominant intermediate (Beck et al., 2002). By using RNO bleaching assay we were
able to quantify the 1O2 quantum yield for each of the photoactive ligand. We found that
the rates of 1O2 generation positively correlated with the level of photo-inactivation. In
addition to supporting our conclusion that the inactivation was 1O2-mediated, these
results also suggested that the rate-limiting step in the photo-inactivation is the excitation
of photosensitizers into 9-fluorenone triplet state biradical. However, the inability of
MB, which also had a quantum yield comparable to the other ligands, to inactivate
EAAT2 also indicated that the loss of activity could not be attributed simply to the
presence of 1O2, and was most likely dependent upon a specific interaction between
protein and ligand.

3.4.2 Photosensitizer-Induced EAAT2 Inactivation Exhibited Different Specificity
A central challenge in all studies employing photoactivable ligands is to establish
that the compounds are indeed modifying the target protein at the desired site. Our
demonstration that the mechanism of inactivation is 1O2-mediated suggested that the
compounds needed to be in close proximity to critical domains needed for transporter
function. It is known that 1O2 species are quenched quickly in aqueous solvents despite
having a longer lifetime than the 9-fluorenone biradicals. Although a 1O2’s diffusion
distance can be as long as 50 nm during its lifetime in aqueous solvents (2 µs), very few
1

O2 generated from photosensitization can reach cells when the photosensitizers are
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included in the cell culture medium (Kochevar and Redmond, 2000; Kanofsky, 1991). In
a report of fluorophore-assisted light inactivation (FALI) using fluorescein-labeled
probes to inactivate β1 integrin, the half-maximal radium of 1O2 damage is estimated to
be 40 Å (Beck et al., 2002).
While the 1O2-based mechanism suggests a close interaction between the ligands
and EAAT2, earlier competition studies pointed out the fact that 9F2C, the most potent
inactivator, does not directly interact with domains responsible for binding the substrate
L-glutamate. The best approach to resolve the issue of specificity is to determine if the
protein can be protected from inactivation by other well known competitive inhibitors. In
the instance of β-2-CFoDA we demonstrated that co-incubation with the potent inhibitor
β-2-FAA effectively protected EAAT2 from inactivation. Interestingly, other inhibitors,
such as TBOA and L-glutamate, showed slight protective effects against β-2-CFoDAinduced photo-inactivation, but the effect did not reach statistical significance level.
These results likely reflect the kinetic difference between the inhibitors within the context
of 60 min incubation time. The dissociation rate for β-2-FAA is markedly longer than
either L-glutamate or TBOA. Thus, even if inhibitor is present at comparable
concentrations (based on the Ki’s), the rapid dissociation of TBOA or L-glutamate would
still allow multiple bindings and unbindings of β-2-CFoDA, and eventually lead to its
inactivation.
In contrast to β-2-CFoDA, β-2-FAA did not protect EAAT2 from inactivation by
9F2C. This result suggests that 9F2C is likely acting at a different site than β-2-CFoDA
to photo-inactivate EAAT2. Such a conclusion is also consistent with the inability of
9F2C to act as a competitive inhibitor of EAAT2. Even though 9F2C does not appear to

97

be acting at the substrate binding domain, it nonetheless must still be in close proximity
to important EAAT2 domains, or it would be inactive as was MB.

3.4.3 Trp472 is the Site of Photo-Oxidation in β-2-CFoDA-Induced EAAT2 Inactivation
The demonstration that β-2-CFoDA was likely binding to the substrate site on
EAAT2 during the processes of photo-inactivation prompted us to look for evidence of
1

O2-mediated modification to the EAAT2 protein. Our previous development of an

expression, isolation and MS characterization protocol for EAAT2 provided an good
starting point for these studies (See Chapter 2). When MALDI-MS analyses were
compared between control and β-2-CFoDA-inactivated proteins, one peptide was
consistently observed at a 16 m/z value greater than the respective control peptide.
Significantly, this peptide spanned residues 388-476 in EAAT2, a portion of sequence
that contributes residues to key component of the presumed substrate domain, including
TM7, HP2 and TM8. Five amino acid residues are particularly susceptible to oxidative
damage induced by 1O2: cysteine, tyrosine, methionine, tryptophan and histidine (Davies,
2003). Within the oxidized peptide 388-476 five such residues are present: M398, Y404,
M415, M450 and W472. Thus, we would suggest that the oxidative modification of one
or more of these residues led to the inactivation of the protein.
The probability or likelihood of the reaction between 1O2 and the side-chains of
amino acids are dependent upon several factors, primarily among which are the distances
from the 1O2 generation site to the amino acid and the rate constants for each reaction. In
aqueous solvents at physiological pH, the rate constants of 1O2-mediated oxidation
reactions on His, Trp, Met, Cys and Tyr are estimated to be 3.2 x 107 dm3 mol-1 s-1, 3.0 x
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107 dm3 mol-1 s-1, 1.6 x 107 dm3 mol-1 s-1, 0.9 x 107 dm3 mol-1 s-1, and 0.8 x 107 dm3 mol-1
s-1, respectively (Wilkinson et al., 1995; Monroe, 1985; Matheson et al., 1975; Rougee et
al., 1988). Other amino acids react with 1O2 much more slowly with rate constants of <
0.7 x 107 dm3 mol-1 s-1 (Wilkinson et al., 1995).
In order to estimate the distances from the 1O2 generation site to the potential
protein modification site(s), molecular docking studies were performed in the Molecular
Computation Core Facility (University of Montana) in collaboration with David Holley
(Ph.D. candidate; BMED). Using Gold (http://www.ccdc.cam.ac.uk/), β-2-CFoDA was
docked into an EAAT2 homology model derived from GltPh crystal structures. A
ChemScore (http://www.ccdc.cam.ac.uk/) algorithm was used to determine the topranked structures. Molecular docking resulted in a parallel alignment of the 9-fluorenone
group with EAAT2 TM8 (Figure 3.12). In three representative docking solutions, the
distances from β-2-CFoDA C9 carbonyls to EAAT2 W472 C3 were 6.22 Å, 6.44 Å and
3.68 Å, respectively. In comparison, the average distances from the same carbonyls to
each of the other 4 candidate residues were 10.49 Å (Y404), 10.75 Å (M450), 14.29 Å
(M398) and 19.32 Å (M415), respectively. It should be noticed that these values only
reflect the “static distances” from the photophore to the residues and did not take
dynamic motions into consideration. However, based on our knowledge of the nature of
the non-substrate EAAT inhibitors, the movements of these inhibitors in the substrate
binding domain are thought to be minimal.
Based on the combination of the relatively higher reaction rate and the spatial
proximity of the β-2-CFoDA 9-fluorenone group to W472 suggested that this residue was
most likely subject to the 1O2-mediated photo-inactivation processes. Mechanistic
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studies of 1O2-mediated tryptophan oxidation revealed multiple pathways and products
including tryptophan alcohol (+16 amu), tryptophan hydroperoxide (+32 amu) and Nformylkynurenine (FMK, +32 amu) (Ronsein et al., 2008; Rosein et al., 2009). Several
tryptophan oxidation products were detected in model peptide samples oxidized by 1O2
(Kim et al., 2008). However, in a protein oxidation study using cytochrome c, only the
Trp+16 adduct was found, indicating that 1O2-mediated tryptophan oxidation reactions
were affected by protein environment (Kim et al., 2008).
The fact that the photo-inactivation was observed in the EAAT1-3 subtypes
suggested the site of oxidation is conserved. Among the five residues, M415 is not
conserved in EAAT1 (V416) or EAAT3 (L384). Mutations of M398 to a cysteine in
GLT-1 (Zarbiv et al., 1998) and EAAT1 (Seal et al., 2000) both abolished the transporter
activity. Y404 was believed to be important in K+ binding of GLT-1 and mutations of
this residue to a Phe, Trp, or Cys led to different levels of activity losses (Zhang et al.,
1998). It was also reported that a W473C mutation in GLAST (W472 in EAAT2) caused
a near-complete loss of transporter activity (Vmax = 14% of control, Seal et al., 2000). We
are not aware of any previous mutagenesis studies on M450 in any of the EAATs.
Attempts to validate and experimentally confirm W472 oxidation at the target of
1

O2-mediated photo-inactivation is limited by the following: 1) point mutations within

this peptide often result in an inactive transporter which would preclude functional
assays; 2) reports that directly identify tryptophan oxidation products using MS-based
approaches are rare (Vanhooren et al., 2002) and most are conducted on model peptides
(Kim et al., 2008); 3) tryptic digestion affords only a scant amount of this peptide, and 4)
the length and hydrophobicity of the peptide that contains W472 poses technical

100

challenges in obtaining MS/MS data. Therefore, at this stage we can only speculate that
the W472 residue is the likely hEAAT2 photo-oxidation site. Future studies employing
an alternative digestion method (such as CNBr) or biophysical technique (i.e. Trp
fluorescence) will likely be needed to provide direct evidence for W472 oxidation and to
identify oxidation product(s).
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Figure 3.12. Molecular docking of β-2-CFoDA into the binding domain of an
EAAT2 model showed the proximity from β-2-CFoDA to W472. Three
representative docking solutions are shown. W472 is in orange. The EAAT2
homology model was derived from the GltPh crystal structures (PDB ID: 2NWW).
Image was rendered using MacPymol (DeLano Scientific,
http://www.delanoscientific.com/).
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3.5 Conclusions

In summary, we used a combination of pharmacological, photochemical, mass
spectrometric and molecular modeling approach to probe the interactions between
EAAT2 and inhibitors. We synthesized and pharmacologically characterized a series of
aryl diaminopropionic acidss and aryl aspartylamide as EAAT inhibitors. We found the
specific lipophilic interaction between the 9-fluorenone or fluorene groups with EAAT
binding domains dictated the inhibitory potencies of such compounds. A 9-fluorenonebearing EAAT2 inhibitor, β-2-CFoDA, was able to bind and produce 1O2 within the
binding domain of protein under UV illumination. The spatial proximity from the 1O2generation site to the susceptible residues allowed the oxidation of residues by 1O2 and
inactivation of EAAT functions. Importantly, we noticed the high specificity of the β-2CFoDA-induced EAAT2 photo-inactivation reactions and the significant protective
effects offered by β-2-FAA, a β-2-CFoDA analogue. These results suggested that 1O2–
mediated, specific binding pocket modification was the mechanism underlying the photoinactivation. We validated the hypothesis by using MALDI-TOF MS tools to inspect the
peptide fingerprint of photo-inactivated EAAT2. We were able to identify a modified
peptide fragment spanning the postulated EAAT2 binding domains and attributed the
mass shift to the oxidation by 1O2 and the addition of either one or two oxygen atoms.
Molecular docking results revealed the proximity from β-2-CFoDA to W472 located on
the TM8 of EAAT2, suggesting W472 was likely to be the oxidation site. These findings
demonstrated the involvement and importance of TM8 in the binding of inhibitors with 9fluorenone and fluorene groups. TM8 is very likely the essential structural component of
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the postulated lipophilic pocket in the EAATs.

The lipophilic pocket structural

differences among different EAAT subtypes may directly contribute to the subtype
selectivity and/or transportability in EAAT inhibitors.

However, we did not see a

subtype difference suggesting other factors related to inactivation predominate inhibitor
binding. The elucidation of the lipophilic interaction will greatly benefit the development
of subtype-selective EAAT targeting drugs.

In addition to the structural-functional

aspect, the results of this study also provided an alternative method to selectively
inactivate the transporter proteins. Recently, a general photo-inactivation method was
reported to selectively inactivate lipophilic pocket-containing proteins (Yogo et al.,
2008). Our method utilizes long wavelength UV light sources and requires relatively
long time to effectively inactivate the proteins. It would be very interesting to modify our
system so visible light source from conventional microscope could be used in direct
tissue slice inactivation.
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